{
  "results": [
    {
      "doc_id": "NCT02756364",
      "section": "Eligibility",
      "claim_id": "c2c73b99-f89c-4dd3-8362-295f9a7965f3",
      "claim_text": "In order to meet the inclusion criteria for the primary trial patients must have had ineffective aromatase inhibitor (AI) therapy before study entry.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Inclusion Criteria:",
      "span_granularity": "sentence",
      "p_entail": 0.0014020286034792662,
      "p_contr": 0.013271590694785118,
      "p_neut": 0.9853264093399048,
      "NLIScore": -0.011869562091305852
    },
    {
      "doc_id": "NCT02756364",
      "section": "Eligibility",
      "claim_id": "0046e113-8ac5-4725-a285-e78b8c26f825",
      "claim_text": "In order to meet the inclusion criteria for the primary trial patients must have had aromatase inhibitor (AI) therapy before study entry, resulting in complete tumor response.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Bone lesions (lytic or mixed [lytic plus sclerotic]) in the absence of measurable disease as defined above. Note: Participants with sclerotic/osteoblastic bone lesions only, in the absence of measurable disease, were not eligible.   Progressive Disease (PD) during prior aromatase inhibitor (AI) therapy.   Have a history of brain metastasis provided that all of the following criteria are met:   Brain metastases have been treated.   No evidence of PD for 3 months before the first dose of study drug.",
      "span_granularity": "paragraph",
      "p_entail": 0.190095916390419,
      "p_contr": 0.03990593180060387,
      "p_neut": 0.7699981927871704,
      "NLIScore": 0.15018998458981514
    },
    {
      "doc_id": "NCT00550771",
      "section": "Eligibility",
      "claim_id": "e6a4e9a6-56b8-4a30-9743-eb02688c090f",
      "claim_text": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Inclusion Criteria:   Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria.   Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules   Subjects must be of female gender and >= 18 years of age   Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics:   node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR   node-negative AND at least one of the following features:   Tumor >2 cm or   Tumor >1 cm and   Negative estrogen receptor/progesterone receptor (ER/PR) or   Malignancy Grade 2-3 or   Presence of peritumoral vascular invasion or   Age <35 years   HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using   immunohistochemistry   Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s])   Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55%   Easter Cooperative Oncology Group (ECOG)-performance status of 0-1   Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN)   Adequate renal function: calculated creatinine clearance >=50 ml/min   Adequate postoperative liver function with a total bilirubin < upper limit of normal (ULN), alkaline phosphatase <2.5 times the ULN and aspartate aminotransferase (AST) <1.5 times the ULN   Subjects must be free of any clinically relevant disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations   Subjects of childbearing potential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening   Subjects must be able to provide written informed consent Exclusion Criteria:   Subject who meets any of the following exclusion criteria will be disqualified from participation in the study:   Clinical or radiological evidence of metastatic disease   Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization   Clinically significant pericardial effusion   Serious cardiac illness including, but not confined to   history of documented congestive heart failure   history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy   history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication   serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias   clinically significant valvular disease   poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg)   Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC)   Pregnancy, or intending to become pregnant during the study   Nursing (breastfeeding) or intending to be nursing during the study   Any of the following clinical conditions:   Chronic obstructive pulmonary disease, requiring chronic treatment   Clinically significant active infections   A history of a psychological illness of condition, preventing the subject to understand the requirements of the study   Unstable regulation of diabetes mellitus   A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study   Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study   Usage of any investigational product within 30 days prior to enrollment   Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study.   Allergy to or sensitivity to the study drug or its excipients",
      "span_granularity": "full-document",
      "p_entail": 0.13438314199447632,
      "p_contr": 0.06654120981693268,
      "p_neut": 0.799075722694397,
      "NLIScore": 0.06784193217754364
    },
    {
      "doc_id": "NCT00550771",
      "section": "Eligibility",
      "claim_id": "016943fa-57ea-4293-8131-03292ea1836c",
      "claim_text": "A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Inclusion Criteria:   Subjects with operable, node-positive or high-risk node-negative (see #3 below) HER2-positive breast carcinoma are eligible for the study, provided they satisfy the following criteria.   Subjects must demonstrate willingness to and be able to participate in the study and to adhere to dose and visit schedules   Subjects must be of female gender and >= 18 years of age   Subjects must have been diagnosed with operable, histologically confirmed adenocarcinoma of the breast with no clinical or radiological evidence of metastatic disease but with otherwise high or intermediate risk tumor characteristics:   node-positive: T1-3, N1-2, M0 (level of T [tumor involvement], N [lymph node involvement], & M [matastases]) OR   node-negative AND at least one of the following features:   Tumor >2 cm or   Tumor >1 cm and   Negative estrogen receptor/progesterone receptor (ER/PR) or   Malignancy Grade 2-3 or   Presence of peritumoral vascular invasion or   Age <35 years   HER2-positive by fluorescence in situ hybridization (FISH)(with gene amplification) or 3+ using   immunohistochemistry   Subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s])   Baseline left ventricular ejection fraction (LVEF) by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO) >=55%   Easter Cooperative Oncology Group (ECOG)-performance status of 0-1   Adequate postoperative bone marrow function with neutrophils >=1.5 x 10^9/l, platelets >=100 x 10^9/l and hemoglobin >= lower limit of normal (LLN)   Adequate renal function: calculated creatinine clearance >=50 ml/min   Adequate postoperative liver function with a total bilirubin < upper limit of normal (ULN), alkaline phosphatase <2.5 times the ULN and aspartate aminotransferase (AST) <1.5 times the ULN   Subjects must be free of any clinically relevant disease that would, in the principal investigator's and/or sponsor's opinion, interfere with the conduct of the study or study evaluations   Subjects of childbearing potential (including women who are less than one year postmenopausal and will be sexually active during the study) must agree to use a medically accepted method of contraception, while receiving protocol-specified medication and for 30 days (or as per local requirements) after stopping the medication or be surgically sterilized prior to screening   Subjects must be able to provide written informed consent Exclusion Criteria:   Subject who meets any of the following exclusion criteria will be disqualified from participation in the study:   Clinical or radiological evidence of metastatic disease   Prior radiotherapy, chemotherapy or biotherapy for the currently diagnosed breast cancer prior to randomization   Clinically significant pericardial effusion   Serious cardiac illness including, but not confined to   history of documented congestive heart failure   history of any form of cardiomyopathy or active treatment for any form of cardiomyopathy   history of angina pectoris or documented transmural myocardial infarction, or active angina pectoris requiring medication   serious ventricular arrhythmias requiring medication or implantable cardioverter-defibrillator (ICD) therapy, uncontrolled supraventricular arrhythmias   clinically significant valvular disease   poorly controlled arterial hypertension (systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg)   Sensory/motor neuropathy > grade 2 as defined by National Cancer Institure - Common Toxicity Criteria (NCI-CTC)   Pregnancy, or intending to become pregnant during the study   Nursing (breastfeeding) or intending to be nursing during the study   Any of the following clinical conditions:   Chronic obstructive pulmonary disease, requiring chronic treatment   Clinically significant active infections   A history of a psychological illness of condition, preventing the subject to understand the requirements of the study   Unstable regulation of diabetes mellitus   A situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study   Is on staff, affiliated with, or a family member of the staff personnel directly involved with this study   Usage of any investigational product within 30 days prior to enrollment   Participation in any other interventional clinical study involving drug, device or biological. This would not prohibit the patient from participating in a quality of life (QOL), questionnaire, blood collection, or observational study.   Allergy to or sensitivity to the study drug or its excipients",
      "span_granularity": "full-document",
      "p_entail": 0.18427921831607819,
      "p_contr": 0.0716843232512474,
      "p_neut": 0.7440364956855774,
      "NLIScore": 0.11259489506483078
    },
    {
      "doc_id": "NCT00723398",
      "section": "Eligibility",
      "claim_id": "d375ef3f-8b35-40eb-b9c0-3fc9592d9bec",
      "claim_text": "Patients with both type 1 and 2 Diabetes are not suitable for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  No hormone replacement therapy for at least six months prior to entry into this study   Non-smokers. Exclusion Criteria:   History of stroke, pulmonary embolism or deep vein thrombosis   History of atherosclerotic heart disease",
      "span_granularity": "paragraph",
      "p_entail": 0.09663405269384384,
      "p_contr": 0.006875954568386078,
      "p_neut": 0.8964900374412537,
      "NLIScore": 0.08975809812545776
    },
    {
      "doc_id": "NCT00723398",
      "section": "Eligibility",
      "claim_id": "d56ffd81-4007-477b-b3c3-0fdb89806931",
      "claim_text": "Patients with diabetes insipidus are not suitable for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  No hormone replacement therapy for at least six months prior to entry into this study   Non-smokers. Exclusion Criteria:   History of stroke, pulmonary embolism or deep vein thrombosis   History of atherosclerotic heart disease",
      "span_granularity": "paragraph",
      "p_entail": 0.22377832233905792,
      "p_contr": 0.02033996395766735,
      "p_neut": 0.7558817863464355,
      "NLIScore": 0.20343835838139057
    },
    {
      "doc_id": "NCT00612560",
      "section": "Eligibility",
      "claim_id": "1bb3badf-41c6-4741-90f0-367473ce254d",
      "claim_text": "children and illiterate adults are not able to take part in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  No competing neoadjuvant or chemotherapy treatment   Time between pre-surgical visit and surgery must be at least 2 weeks   No chemotherapy in the past 12 months Exclusion Criteria:   Inability to read and write English",
      "span_granularity": "paragraph",
      "p_entail": 0.20841769874095917,
      "p_contr": 0.012975480407476425,
      "p_neut": 0.7786068320274353,
      "NLIScore": 0.19544221833348274
    },
    {
      "doc_id": "NCT00612560",
      "section": "Eligibility",
      "claim_id": "9b6bd158-a66d-42b6-8fe6-843ff05e0c8d",
      "claim_text": "children and illiterate adults are able to take part in the primary trial, unless they can read and write in italian.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Willingness to avoid herbal and dietary supplements (not including vitamins), aspirin, and ibuprofen during the intervention period",
      "span_granularity": "sentence",
      "p_entail": 0.02307036891579628,
      "p_contr": 0.5442839860916138,
      "p_neut": 0.4326455891132355,
      "NLIScore": -0.5212136171758175
    },
    {
      "doc_id": "NCT02186015",
      "section": "Eligibility",
      "claim_id": "2825d63b-8f22-4fb8-829f-9567845251c6",
      "claim_text": "adults and children can take part in the primary trial",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Any race/ethnicity   English speaking   No changes to MBC treatments within 30 days of enrollment and/or deemed clinically stable by their treating physician   Willingness to sign a written informed consent and complete questionnaires   Cease ingestion of vitamin D supplementation not study related",
      "span_granularity": "paragraph",
      "p_entail": 0.06375640630722046,
      "p_contr": 0.00760509492829442,
      "p_neut": 0.9286385178565979,
      "NLIScore": 0.05615131137892604
    },
    {
      "doc_id": "NCT02186015",
      "section": "Eligibility",
      "claim_id": "a805f174-2707-4302-a195-05153ea8523e",
      "claim_text": "Only adults can take part in the primary trial",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Exclusion Criteria:",
      "span_granularity": "sentence",
      "p_entail": 0.0041377488523721695,
      "p_contr": 0.008502583019435406,
      "p_neut": 0.9873597025871277,
      "NLIScore": -0.004364834167063236
    },
    {
      "doc_id": "NCT00399529",
      "section": "Eligibility",
      "claim_id": "3c7ecca8-5397-41f5-b72b-84217bf3acd2",
      "claim_text": "Women with chronic obstructive pulmonary disease that does not require systemic corticosteroids, are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  No systemic oral steroids administered within 28 days prior to initiating treatment on protocol. Topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes.   No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.   Not pregnant, and on appropriate birth control if of child-bearing potential.   No history of other malignancies within the prior five years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, and superficial bladder cancer).   Adequate bone marrow reserve with absolute neutrophil count (ANC) > 1000 and platelets > 100,000.",
      "span_granularity": "paragraph",
      "p_entail": 0.7366204857826233,
      "p_contr": 0.018261294811964035,
      "p_neut": 0.24511826038360596,
      "NLIScore": 0.7183591909706593
    },
    {
      "doc_id": "NCT00399529",
      "section": "Eligibility",
      "claim_id": "c6ca8c6a-7eae-4671-9eff-c44a1222fadb",
      "claim_text": "Women with rheumatoid arthritis that does not require systemic corticosteroids for treatment, are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  No systemic oral steroids administered within 28 days prior to initiating treatment on protocol. Topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes.   No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.   Not pregnant, and on appropriate birth control if of child-bearing potential.   No history of other malignancies within the prior five years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, and superficial bladder cancer).   Adequate bone marrow reserve with absolute neutrophil count (ANC) > 1000 and platelets > 100,000.",
      "span_granularity": "paragraph",
      "p_entail": 0.6067193746566772,
      "p_contr": 0.04056684300303459,
      "p_neut": 0.3527137339115143,
      "NLIScore": 0.5661525316536427
    },
    {
      "doc_id": "NCT01831089",
      "section": "Eligibility",
      "claim_id": "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0",
      "claim_text": "Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Inclusion Criteria:   Voluntarily signed and dated written informed consent   Age between 18 and 75 years old (both inclusive)   Eastern Cooperative Oncology Group (ECOG) performance status (PS) of  1   Life expectancy  3 months.",
      "span_granularity": "paragraph",
      "p_entail": 0.13260307908058167,
      "p_contr": 0.01220704149454832,
      "p_neut": 0.8551898002624512,
      "NLIScore": 0.12039603758603334
    },
    {
      "doc_id": "NCT01831089",
      "section": "Eligibility",
      "claim_id": "e8e3fedb-075d-440e-bf2e-baec76f96cca",
      "claim_text": "Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Inclusion Criteria:   Voluntarily signed and dated written informed consent   Age between 18 and 75 years old (both inclusive)   Eastern Cooperative Oncology Group (ECOG) performance status (PS) of  1   Life expectancy  3 months.   Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors:   Breast cancer   Epithelial ovarian cancer or gynecological cancer   Head and neck squamous cell carcinoma   Non-small cell lung cancer   Small cell lung cancer   Platinum-refractory germ-cell tumors.   Adenocarcinoma or carcinoma of unknown primary site   Adequate bone marrow, renal, hepatic, and metabolic function   Recovery to grade  1 or to baseline from any Adverse Event (AE) derived from previous treatment (excluding alopecia of any grade).   Pre-menopausal women must have a negative pregnancy test before study entry and agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuation Exclusion Criteria:   Prior treatment with PM01183 or weekly paclitaxel or nanoalbumin-paclitaxel   Patients who have previously discontinued paclitaxel-based regimes due to drug related toxicity.   Known hypersensitivity to bevacizumab or any component of its formulation   Patients who have previously discontinued bevacizumab-containing regimes due to drug-related toxicity.   More than three prior lines of chemotherapy   Less than three months since last taxane-containing therapy.   Wash-out period:   Less than three weeks since the last chemotherapy-containing regimen   Less than three weeks since the last radiotherapy dose   Less than four weeks since last monoclonal antibody-containing therapy   Concomitant diseases/conditions:   Unstable angina, myocardial infarction, valvular heart disease, encephalopathy, ischemic attacks, hemorrhagic or ischemic cerebrovascular accident (CVA) or ongoing pulmonary embolism within last year, arrhythmia, hepatopathy, uncontrolled infection, hemoptysis or oxygen requiring dyspnea, known HIV infection, bleeding risk, muscular problems, peripheral neuropathy, Symptomatic or progressive brain metastases or leptomeningeal disease.   Men or pre-menopausal women who are not using an effective method of contraception as previously described; actively breast feeding women.   Patients who have pelvic irradiation with doses  45 Grays (Gy).   History of previous bone marrow and/or stem cell transplantation.   Confirmed bone marrow involvement",
      "span_granularity": "full-document",
      "p_entail": 0.35597988963127136,
      "p_contr": 0.1720370203256607,
      "p_neut": 0.4719831645488739,
      "NLIScore": 0.18394286930561066
    },
    {
      "doc_id": "NCT01831089",
      "section": "Eligibility",
      "claim_id": "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0",
      "claim_text": "Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Small cell lung cancer   Platinum-refractory germ-cell tumors.   Adenocarcinoma or carcinoma of unknown primary site   Adequate bone marrow, renal, hepatic, and metabolic function   Recovery to grade  1 or to baseline from any Adverse Event (AE) derived from previous treatment (excluding alopecia of any grade).",
      "span_granularity": "paragraph",
      "p_entail": 0.28377214074134827,
      "p_contr": 0.1035388857126236,
      "p_neut": 0.6126889586448669,
      "NLIScore": 0.18023325502872467
    },
    {
      "doc_id": "NCT01831089",
      "section": "Eligibility",
      "claim_id": "e8e3fedb-075d-440e-bf2e-baec76f96cca",
      "claim_text": "Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Platinum-refractory germ-cell tumors.   Adenocarcinoma or carcinoma of unknown primary site   Adequate bone marrow, renal, hepatic, and metabolic function   Recovery to grade  1 or to baseline from any Adverse Event (AE) derived from previous treatment (excluding alopecia of any grade).   Pre-menopausal women must have a negative pregnancy test before study entry and agree to use a medically acceptable method of contraception throughout the treatment period and for at least six weeks after treatment discontinuation",
      "span_granularity": "paragraph",
      "p_entail": 0.30817359685897827,
      "p_contr": 0.13129018247127533,
      "p_neut": 0.56053626537323,
      "NLIScore": 0.17688341438770294
    },
    {
      "doc_id": "NCT00076024",
      "section": "Eligibility",
      "claim_id": "f4e0551c-44e9-44f1-9a50-c65075a51715",
      "claim_text": "There are no conditions on hepatic function for participants of the primary trial",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)",
      "span_granularity": "sentence",
      "p_entail": 0.0030869669280946255,
      "p_contr": 0.7137332558631897,
      "p_neut": 0.28317973017692566,
      "NLIScore": -0.7106462889350951
    },
    {
      "doc_id": "NCT00076024",
      "section": "Eligibility",
      "claim_id": "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72",
      "claim_text": "There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)",
      "span_granularity": "sentence",
      "p_entail": 0.004128555301576853,
      "p_contr": 0.46591487526893616,
      "p_neut": 0.5299565196037292,
      "NLIScore": -0.4617863199673593
    },
    {
      "doc_id": "NCT00076024",
      "section": "Eligibility",
      "claim_id": "f4e0551c-44e9-44f1-9a50-c65075a51715",
      "claim_text": "There are no conditions on hepatic function for participants of the primary trial",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)",
      "span_granularity": "sentence",
      "p_entail": 0.0030869669280946255,
      "p_contr": 0.7137332558631897,
      "p_neut": 0.28317973017692566,
      "NLIScore": -0.7106462889350951
    },
    {
      "doc_id": "NCT00076024",
      "section": "Eligibility",
      "claim_id": "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72",
      "claim_text": "There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)",
      "span_granularity": "sentence",
      "p_entail": 0.004128555301576853,
      "p_contr": 0.46591487526893616,
      "p_neut": 0.5299565196037292,
      "NLIScore": -0.4617863199673593
    },
    {
      "doc_id": "NCT00121134",
      "section": "Eligibility",
      "claim_id": "50a2a4a9-2b30-4901-b7bc-9c77b8ca870f",
      "claim_text": "the primary trial requires participants to have undergone definitive resection of primary tumor.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Inclusion Criteria:   Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging   Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.   Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.   For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy.",
      "span_granularity": "paragraph",
      "p_entail": 0.4722078740596771,
      "p_contr": 0.025794655084609985,
      "p_neut": 0.5019974112510681,
      "NLIScore": 0.44641321897506714
    },
    {
      "doc_id": "NCT00121134",
      "section": "Eligibility",
      "claim_id": "edcae553-8a0a-45d2-a0fa-4db68608ef03",
      "claim_text": "the primary trial requires participants to have a primary tumor > 5cm in longest dimension.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Inclusion Criteria:   Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging   Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.   Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.   For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy.",
      "span_granularity": "paragraph",
      "p_entail": 0.1769646257162094,
      "p_contr": 0.15405845642089844,
      "p_neut": 0.668976902961731,
      "NLIScore": 0.022906169295310974
    },
    {
      "doc_id": "NCT00605267",
      "section": "Eligibility",
      "claim_id": "91cf53f9-7233-49ee-a619-c027f6db67ac",
      "claim_text": "Only women can be eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Inclusion Criteria:   Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent Exclusion Criteria:   Medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT).",
      "span_granularity": "full-document",
      "p_entail": 0.08382231742143631,
      "p_contr": 0.009999820031225681,
      "p_neut": 0.9061778783798218,
      "NLIScore": 0.07382249739021063
    },
    {
      "doc_id": "NCT00605267",
      "section": "Eligibility",
      "claim_id": "ab52c559-5712-44ff-becd-1c491e107472",
      "claim_text": "Men are not eligible for the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Exclusion Criteria:",
      "span_granularity": "sentence",
      "p_entail": 0.015239104628562927,
      "p_contr": 0.017997704446315765,
      "p_neut": 0.9667631983757019,
      "NLIScore": -0.002758599817752838
    },
    {
      "doc_id": "NCT01142661",
      "section": "Eligibility",
      "claim_id": "18d9991c-ca96-4bab-93af-77654857a07f",
      "claim_text": "the primary trial does not accept patients with grade 1 alopecia.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Female subjects of childbearing potential must agree to be abstinent or to use a highly effective methods of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intra-uterine device, or have a vasectomised partner) having started for at least one menstrual cycle prior to starting eribulin and throughout the entire treatment period and for 30 days (longer if appropriate) after the last dose of eribulin. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.   Exclusion Criteria Subjects who meet any of the following criteria will be excluded from participation in the treatment protocol:   Eligible for any other eribulin study that is open in the same region.   Existing anti-cancer therapy-related toxicities of Grade >/= 2, except that alopecia and Grade 2 neuropathy are acceptable.   History of congestive heart failure with New York Heart Association Classification >II, unstable angina, myocardial infarction within the past 6 months, serious cardiac arrhythmia.",
      "span_granularity": "paragraph",
      "p_entail": 0.27883484959602356,
      "p_contr": 0.08877039700746536,
      "p_neut": 0.6323947906494141,
      "NLIScore": 0.1900644525885582
    },
    {
      "doc_id": "NCT01142661",
      "section": "Eligibility",
      "claim_id": "c0b528ef-ae9f-4c01-8915-b47856f07c95",
      "claim_text": "the primary trial accepts patients with grade 3 neuropathy.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Serum creatinine </= 2.0 mg/dL or creatinine clearance >/= 40 mL/min according to Cockcroft and Gault formula.   Absolute neutrophil count >/= 1.5 x 10^9/L, hemoglobin >/= 10 g/dL (can be corrected by growth factor or transfusion), and platelet count >/= 100 x 10^9/L.   Total bilirubin </= 1.5 x upper limit of normal (ULN). Alkaline phosphatase (AP), alanine aminotransferase, and aspartate aminotransferase </= 3 x ULN (</= 5 x ULN in case of liver metastases). In case AP is >3 x ULN (in absence of liver metastases) or >5 x ULN (in presence of liver metastases) AND subject also is known to have bone metastases, the liver specific AP must be separated from the total and used to assess the liver function instead of the total AP.   Are willing and able to comply with all aspects of the treatment protocol.   Provide written informed consent.",
      "span_granularity": "paragraph",
      "p_entail": 0.054583992809057236,
      "p_contr": 0.048464082181453705,
      "p_neut": 0.8969519138336182,
      "NLIScore": 0.006119910627603531
    },
    {
      "doc_id": "NCT01009918",
      "section": "Eligibility",
      "claim_id": "e436827b-10db-4179-bf8f-07786ee6145b",
      "claim_text": "There are no racial criteria for entry into the primary trial, however there are gender criteria.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  This protocol does not exclude patients who are participating on other investigational studies. Refer to the local IRB guidelines.",
      "span_granularity": "sentence",
      "p_entail": 0.0021679820492863655,
      "p_contr": 0.039497509598731995,
      "p_neut": 0.9583345651626587,
      "NLIScore": -0.03732952754944563
    },
    {
      "doc_id": "NCT01527487",
      "section": "Eligibility",
      "claim_id": "4c0ffc50-5cb2-4574-b954-335d142edbe4",
      "claim_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Valvular disease with significant compromise in cardiac function   Chronic use of drugs that cause QTc prolongation. Patients must discontinue use of these drugs 7 days prior to the start of study treatment.   Presence of other active cancers, or history of treatment for invasive cancer 5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.   Patients may not receive any other investigational or anti-cancer treatments while participating in this trial.   Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.",
      "span_granularity": "paragraph",
      "p_entail": 0.07226698100566864,
      "p_contr": 0.00861319899559021,
      "p_neut": 0.9191198348999023,
      "NLIScore": 0.06365378201007843
    },
    {
      "doc_id": "NCT01527487",
      "section": "Eligibility",
      "claim_id": "73cfc4ea-afc0-465b-a403-c1bd771ded33",
      "claim_text": "Patients prescribed Citalopram as an ongoing treatment for depression are not eligible for the primary trial, as Psychological illnesses are not permitted.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Valvular disease with significant compromise in cardiac function   Chronic use of drugs that cause QTc prolongation. Patients must discontinue use of these drugs 7 days prior to the start of study treatment.   Presence of other active cancers, or history of treatment for invasive cancer 5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.   Patients may not receive any other investigational or anti-cancer treatments while participating in this trial.   Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.",
      "span_granularity": "paragraph",
      "p_entail": 0.09658773243427277,
      "p_contr": 0.00895859207957983,
      "p_neut": 0.8944537043571472,
      "NLIScore": 0.08762914035469294
    },
    {
      "doc_id": "NCT02878057",
      "section": "Eligibility",
      "claim_id": "a79fc503-215f-40d4-9cc1-e101cec3a9c9",
      "claim_text": "Patients that are fully active and able to carry on all pre-disease performance without restriction are excluded from the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  With hypertension and the blood pressure cannot be reduced to the normal range through antihypertensive drug treatment (systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 90 mmHg).",
      "span_granularity": "sentence",
      "p_entail": 0.002559361746534705,
      "p_contr": 0.0906180813908577,
      "p_neut": 0.9068225026130676,
      "NLIScore": -0.08805871964432299
    },
    {
      "doc_id": "NCT02878057",
      "section": "Eligibility",
      "claim_id": "3cd353ed-af0d-4356-8f45-efc1e91a2a0d",
      "claim_text": "Patients that are ambulatory and capable of all selfcare but unable to carry out any work activities, are excluded from the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Exclusion Criteria:",
      "span_granularity": "sentence",
      "p_entail": 0.014966650865972042,
      "p_contr": 0.01987050473690033,
      "p_neut": 0.9651628732681274,
      "NLIScore": -0.0049038538709282875
    },
    {
      "doc_id": "NCT00853996",
      "section": "Eligibility",
      "claim_id": "3fa58451-21ba-4ad9-8d13-6a9eefa17a5b",
      "claim_text": "Women classified as high-risk of developing breast cancer within the next 5 years and within her lifetime by the Gail model are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Inclusion Criteria:   Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group   Premenopausal   More than 6 months since initiating or discontinuing oral contraceptives   At increased risk for breast cancer, as indicated by >= 1 of the following risk factors:",
      "span_granularity": "paragraph",
      "p_entail": 0.32846084237098694,
      "p_contr": 0.0042065344750881195,
      "p_neut": 0.6673325896263123,
      "NLIScore": 0.3242543078958988
    },
    {
      "doc_id": "NCT00853996",
      "section": "Eligibility",
      "claim_id": "70912726-ba1b-47ef-9005-9584c8caf559",
      "claim_text": "Women classified as low-risk of developing breast cancer within the next 5 years by the Gail model, and no Family history consistent with hereditary breast cancer, are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Creatinine < 1.5 mg/dL   Alkaline phosphatase < 2 times ULN   Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment   Fertile patients must use effective contraception during and for 3 months after completion of study treatment   Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)",
      "span_granularity": "paragraph",
      "p_entail": 0.1148427277803421,
      "p_contr": 0.020667899399995804,
      "p_neut": 0.8644893765449524,
      "NLIScore": 0.0941748283803463
    },
    {
      "doc_id": "NCT02988986",
      "section": "Eligibility",
      "claim_id": "c68f6822-24fa-44b5-bf63-c272a8031fab",
      "claim_text": "Patients must have either AST or ALT < 1.5 ULN to participate in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Hepatic status: Serum total bilirubin  1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase  1.5 x ULN, and alkaline phosphatase  1.5 x ULN;   Renal status: Creatinine clearance 50 mL/min based on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour);   Metabolic status: HbA1c < 7.0%, fasting serum glucose  130 mg/dL, and fasting triglycerides  300 mg/dL.   Ability to swallow oral medications.   Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",
      "span_granularity": "paragraph",
      "p_entail": 0.3495318591594696,
      "p_contr": 0.09146854281425476,
      "p_neut": 0.5589996576309204,
      "NLIScore": 0.25806331634521484
    },
    {
      "doc_id": "NCT02988986",
      "section": "Eligibility",
      "claim_id": "2b79f9cc-4262-4353-ad28-91cda07a9b9a",
      "claim_text": "Patients must have AST, ALP and ALT < 1.5 ULN to participate in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Hepatic status: Serum total bilirubin  1 x upper limit of normal (ULN; in the case of known Gilbert's syndrome, a higher serum total bilirubin [< 1.5 x ULN] is allowed), aspartate aminotransferase and alanine aminotransferase  1.5 x ULN, and alkaline phosphatase  1.5 x ULN;   Renal status: Creatinine clearance 50 mL/min based on Cockcroft-Gault estimate or based on urine collection (12 or 24 hour);   Metabolic status: HbA1c < 7.0%, fasting serum glucose  130 mg/dL, and fasting triglycerides  300 mg/dL.   Ability to swallow oral medications.   Voluntary written consent must be given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.",
      "span_granularity": "paragraph",
      "p_entail": 0.4376974105834961,
      "p_contr": 0.05463002249598503,
      "p_neut": 0.5076725482940674,
      "NLIScore": 0.38306738808751106
    },
    {
      "doc_id": "NCT02995980",
      "section": "Eligibility",
      "claim_id": "51cf1333-78b1-410a-82fe-aabfaa00a840",
      "claim_text": "A patient presenting a Glomerular filtration rate of 63, a severe iodinated contrast allergy, and with BI-RADS category c breast tissue would be eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  History of iodinated contrast allergy   Pregnant or lactating as determined by routine standard practice   Personal history of breast cancer   History of prior breast excisional biopsy (Patients with a history of core needle biopsy will not be excluded)   History of prior breast reduction mammoplasty surgery",
      "span_granularity": "paragraph",
      "p_entail": 0.08087736368179321,
      "p_contr": 0.04680005460977554,
      "p_neut": 0.8723225593566895,
      "NLIScore": 0.03407730907201767
    },
    {
      "doc_id": "NCT02995980",
      "section": "Eligibility",
      "claim_id": "e1f6d1b3-92eb-4ad8-8c00-e44b58650e62",
      "claim_text": "A patient presenting a Glomerular filtration rate of 63 and with BI-RADS category c breast tissue would be eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Signed informed consent",
      "span_granularity": "sentence",
      "p_entail": 0.07780789583921432,
      "p_contr": 0.04023342952132225,
      "p_neut": 0.8819586634635925,
      "NLIScore": 0.037574466317892075
    },
    {
      "doc_id": "NCT00376597",
      "section": "Eligibility",
      "claim_id": "b1dd7632-ed92-40a9-9293-bce68619c658",
      "claim_text": "Patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study; however, it should be documented appropriately on form C-1628 at the conclusion of study participation",
      "span_granularity": "sentence",
      "p_entail": 0.2258007675409317,
      "p_contr": 0.01910366490483284,
      "p_neut": 0.7550955414772034,
      "NLIScore": 0.20669710263609886
    },
    {
      "doc_id": "NCT00376597",
      "section": "Eligibility",
      "claim_id": "75a65913-5655-4377-b441-ecdd4dd75175",
      "claim_text": "Patients with stage 4 cancer are excluded from the primary trial",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Patients with double mastectomy, axillary node dissection and/or radiation on both arms are ineligible; patients who undergo these treatments (i.e., surgery and/or radiation) on the contralateral arm after registration to Step 2 are still eligible to remain in the study; however, it should be documented appropriately on form C-1628 at the conclusion of study participation",
      "span_granularity": "sentence",
      "p_entail": 0.1373707503080368,
      "p_contr": 0.013747801072895527,
      "p_neut": 0.8488814830780029,
      "NLIScore": 0.12362294923514128
    },
    {
      "doc_id": "NCT01964924",
      "section": "Eligibility",
      "claim_id": "afdafe17-63a8-4fca-b923-a2bb964493d1",
      "claim_text": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], gingko biloba, yohimbe, saw palmetto, or ginseng)   Patients receiving strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible   History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes; visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure > 21 mm Hg   Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements   Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795",
      "span_granularity": "paragraph",
      "p_entail": 0.4137808084487915,
      "p_contr": 0.05670866742730141,
      "p_neut": 0.529510498046875,
      "NLIScore": 0.3570721410214901
    },
    {
      "doc_id": "NCT01964924",
      "section": "Eligibility",
      "claim_id": "7814620b-23de-463b-8fd1-efdf51ce26b3",
      "claim_text": "an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])   Patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer   Patients must consent to both a pretreatment and a post-treatment mandatory research biopsy prior to enrolling on trial, and therefore, must have tissue (excluding bone or brain) that is amenable to biopsy   Eastern Cooperative Oncology Group (ECOG) performance status 0-1   Life expectancy of greater than 3 months",
      "span_granularity": "paragraph",
      "p_entail": 0.23612339794635773,
      "p_contr": 0.019742030650377274,
      "p_neut": 0.7441346049308777,
      "NLIScore": 0.21638136729598045
    },
    {
      "doc_id": "NCT01964924",
      "section": "Eligibility",
      "claim_id": "afdafe17-63a8-4fca-b923-a2bb964493d1",
      "claim_text": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  The concurrent use of all herbal supplements is prohibited during the study (including, but not limited to, St. John's wort, kava, ephedra [ma huang], gingko biloba, yohimbe, saw palmetto, or ginseng)   Patients receiving strong inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible   History or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR) or predisposing factors to RVO or CSR (e.g., uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, history of hyperviscosity or hypercoagulability syndromes; visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as evidence of new optic disc cupping, evidence of new visual field defects, and intraocular pressure > 21 mm Hg   Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements   Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK2141795",
      "span_granularity": "paragraph",
      "p_entail": 0.4137808084487915,
      "p_contr": 0.05670866742730141,
      "p_neut": 0.529510498046875,
      "NLIScore": 0.3570721410214901
    },
    {
      "doc_id": "NCT01964924",
      "section": "Eligibility",
      "claim_id": "7814620b-23de-463b-8fd1-efdf51ce26b3",
      "claim_text": "an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1])   Patients must have had exposure to at least 1 and no more than 3 prior chemotherapy regimens for the treatment of metastatic breast cancer   Patients must consent to both a pretreatment and a post-treatment mandatory research biopsy prior to enrolling on trial, and therefore, must have tissue (excluding bone or brain) that is amenable to biopsy   Eastern Cooperative Oncology Group (ECOG) performance status 0-1   Life expectancy of greater than 3 months",
      "span_granularity": "paragraph",
      "p_entail": 0.23612339794635773,
      "p_contr": 0.019742030650377274,
      "p_neut": 0.7441346049308777,
      "NLIScore": 0.21638136729598045
    },
    {
      "doc_id": "NCT01772004",
      "section": "Eligibility",
      "claim_id": "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2",
      "claim_text": "African-american patients can participate in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  Inclusion Criteria for expansion phase:",
      "span_granularity": "sentence",
      "p_entail": 0.06020951643586159,
      "p_contr": 0.034405410289764404,
      "p_neut": 0.9053851366043091,
      "NLIScore": 0.025804106146097183
    },
    {
      "doc_id": "NCT01772004",
      "section": "Eligibility",
      "claim_id": "574106ef-1b9c-4540-a89f-5100a9bbe798",
      "claim_text": "African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study.",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Inclusion Criteria for expansion phase:",
      "span_granularity": "sentence",
      "p_entail": 0.020657096058130264,
      "p_contr": 0.021018095314502716,
      "p_neut": 0.9583247900009155,
      "NLIScore": -0.0003609992563724518
    },
    {
      "doc_id": "NCT01772004",
      "section": "Eligibility",
      "claim_id": "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2",
      "claim_text": "African-american patients can participate in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Inclusion Criteria for expansion phase:",
      "span_granularity": "sentence",
      "p_entail": 0.06020951643586159,
      "p_contr": 0.034405410289764404,
      "p_neut": 0.9053851366043091,
      "NLIScore": 0.025804106146097183
    },
    {
      "doc_id": "NCT01772004",
      "section": "Eligibility",
      "claim_id": "574106ef-1b9c-4540-a89f-5100a9bbe798",
      "claim_text": "African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Inclusion Criteria for expansion phase:",
      "span_granularity": "sentence",
      "p_entail": 0.020657096058130264,
      "p_contr": 0.021018095314502716,
      "p_neut": 0.9583247900009155,
      "NLIScore": -0.0003609992563724518
    },
    {
      "doc_id": "NCT02027376",
      "section": "Eligibility",
      "claim_id": "b841dfd8-4676-4d3c-a57d-6ba1055b8597",
      "claim_text": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued 2 months prior to study entry and the patient has fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Patients with untreated brain metastases. However, a patient with Central Nervous System (CNS) metastases may participate in this trial if > 4 weeks from therapy completion (incl. radiation and/or surgery), is clinically stable with respect to the tumor at the time of study entry and is not receiving corticosteroid therapy.",
      "span_granularity": "sentence",
      "p_entail": 0.004178961738944054,
      "p_contr": 0.05743300914764404,
      "p_neut": 0.9383879899978638,
      "NLIScore": -0.05325404740869999
    },
    {
      "doc_id": "NCT02027376",
      "section": "Eligibility",
      "claim_id": "b838a265-99e4-42f0-bd72-b4f72d7eb16e",
      "claim_text": "A patient was treated with Pertuzumab for 6 months, and this treatment was discontinued less than 1 month prior to study entry and the patient has not fully recovered from the entailing side effects, hence this patient is eligible for the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Patients who have received biologic therapy (e.g. antibodies)  4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy.",
      "span_granularity": "sentence",
      "p_entail": 0.008731052279472351,
      "p_contr": 0.01352644618600607,
      "p_neut": 0.9777424931526184,
      "NLIScore": -0.004795393906533718
    },
    {
      "doc_id": "NCT00121836",
      "section": "Eligibility",
      "claim_id": "80726ab0-e8e4-4c42-860b-fdedad407517",
      "claim_text": "Patients that are not willing to sign and give written informed consent for participation of the primary trial will still be included.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer",
      "span_granularity": "sentence",
      "p_entail": 0.0029877189081162214,
      "p_contr": 0.33510351181030273,
      "p_neut": 0.6619088053703308,
      "NLIScore": -0.3321157929021865
    },
    {
      "doc_id": "NCT01305941",
      "section": "Eligibility",
      "claim_id": "e8b8c2b7-612d-4bab-b8a6-3dbc756cc210",
      "claim_text": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being triple-positive.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (>/=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy, stereotactic radiosurgery, gamma knife, or equivalent). Patients in whom brain metastases (BM) are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible.",
      "span_granularity": "sentence",
      "p_entail": 0.2667625844478607,
      "p_contr": 0.07434716075658798,
      "p_neut": 0.6588901877403259,
      "NLIScore": 0.19241542369127274
    },
    {
      "doc_id": "NCT01305941",
      "section": "Eligibility",
      "claim_id": "dd98fca1-27a7-41c2-ba0c-3ff90aceab54",
      "claim_text": "Patients must present IHC 3+ or FISH amplified results to participate in the primary trial, meaning their cancer is Histologically-confirmed as being HER2-positive.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization (FISH) amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (>/=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy, stereotactic radiosurgery, gamma knife, or equivalent). Patients in whom brain metastases (BM) are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible.",
      "span_granularity": "sentence",
      "p_entail": 0.27187007665634155,
      "p_contr": 0.030244167894124985,
      "p_neut": 0.6978856921195984,
      "NLIScore": 0.24162590876221657
    },
    {
      "doc_id": "NCT00834678",
      "section": "Eligibility",
      "claim_id": "525ed182-07e9-4548-87b3-c831e0b7389e",
      "claim_text": "Patients with lymphopenia can participate in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Prior adjuvant or neoadjuvant chemotherapy and 1 prior chemotherapy regimen in the metastatic setting allowed provided recovered from all acute toxicities",
      "span_granularity": "sentence",
      "p_entail": 0.11460941284894943,
      "p_contr": 0.016073077917099,
      "p_neut": 0.8693174123764038,
      "NLIScore": 0.09853633493185043
    },
    {
      "doc_id": "NCT00834678",
      "section": "Eligibility",
      "claim_id": "a577e819-c928-4217-8743-f4809e852919",
      "claim_text": "Patients must have a white blood cell count above 1,500/mm\u00b3 to participate in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "DISEASE CHARACTERISTICS:   Histologically confirmed breast cancer meeting 1 of the following criteria:   Unresectable stage IIIB or IIIC disease   Stage IV disease   Must be negative for all of the following:   Estrogen receptor (< 10%)   Progesterone receptor (<10%)   HER-2 (negative FISH, IHC 0 - 1+, or IHC +2 with negative FISH)   Measurable or evaluable disease   No symptomatic or progressive CNS (central nervous system) metastases   Previously treated CNS metastases allowed provided all of the following criteria are met:   At least 8 weeks since prior radiation to brain or CNS metastases   No concurrent steroids   No leptomeningeal disease   PATIENT CHARACTERISTICS:   Menopausal status not specified   ECOG (Eastern Cooperative Oncology Group) performance status 0-2   Life expectancy  6 months   WBC > 1,500/mm\u00b3   Platelet count > 100,000/mm\u00b3   Creatinine clearance > 40 mL/min   Normal electrolytes (i.e., Na, K, and Ca normal; minor deviations are allowed if they do not impact on patient safety in the clinical judgment of the treating physician)   Bilirubin  1.5 times upper limit of normal (ULN)   ALT and AST  2.5 times ULN ( 5 times ULN in the presence of documented liver metastases)   Alkaline phosphatase  2.5 times ULN ( 5 times ULN in the presence of liver or bone metastases)   Not pregnant or nursing   Fertile patients must use effective barrier contraception   No uncontrolled intercurrent illness   No active infection requiring systemic therapy   Able to swallow oral medications and with no medical problems or prior surgeries that may interfere with the absorption of oral medications including the following:   Uncontrolled nausea, vomiting, or diarrhea   Lack of the physical integrity of the upper gastrointestinal tract   Malabsorption syndrome   No known hypersensitivity to bendamustine hydrochloride, mannitol, or erlotinib hydrochloride   No prior malignancy in the past 5 years except for adequately treated basal cell or squamous cell skin carcinoma, or adequately treated stage I-II cancer for which the patient is in complete remission   PRIOR CONCURRENT THERAPY:   See Disease Characteristics   Prior adjuvant or neoadjuvant chemotherapy and 1 prior chemotherapy regimen in the metastatic setting allowed provided recovered from all acute toxicities   No prior bendamustine hydrochloride or EGFR-directed therapy   No other concurrent antineoplastic treatments, including radiotherapy, chemotherapy, biological therapy, hormonal therapy, immunotherapy, gene therapy, and surgery   Intravenous bisphosphonates allowed   No concurrent antiretroviral therapy for HIV-positive patients   No other concurrent investigational agents",
      "span_granularity": "full-document",
      "p_entail": 0.348466157913208,
      "p_contr": 0.09360848367214203,
      "p_neut": 0.5579254031181335,
      "NLIScore": 0.254857674241066
    },
    {
      "doc_id": "NCT00232479",
      "section": "Eligibility",
      "claim_id": "33ef3abf-97c0-4d15-909d-258fb47ac54a",
      "claim_text": "Only patients with HER2 positive breast carcinoma are eligible for the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  HER-2 overexpressing breast cancer",
      "span_granularity": "sentence",
      "p_entail": 0.0015239882050082088,
      "p_contr": 0.013987543992698193,
      "p_neut": 0.9844883680343628,
      "NLIScore": -0.012463555787689984
    },
    {
      "doc_id": "NCT00232479",
      "section": "Eligibility",
      "claim_id": "e7899445-9b80-4429-b4c3-d47bd36a2347",
      "claim_text": "Patients with HER2 positive breast or colon carcinoma are eligible for the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Metastatic disease",
      "span_granularity": "sentence",
      "p_entail": 0.014399271458387375,
      "p_contr": 0.023386238142848015,
      "p_neut": 0.962214469909668,
      "NLIScore": -0.00898696668446064
    },
    {
      "doc_id": "NCT01827163",
      "section": "Eligibility",
      "claim_id": "1a6661e0-343f-4056-b568-611e7cc7750c",
      "claim_text": "Any patients with breast cancer above stage, currently receiving radiation therapy or biotherapy are excluded from the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause. LVEF by ECHO (with strain if possible) with LVEF of  50%. If an ECHO cannot be done, a MUGA may be performed.   Patients must give written, informed consent indicating their understanding of and willingness to participate in the study. Exclusion Criteria:   Patients with stage IV breast cancer or undergoing chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.   Pregnant or breastfeeding patients.",
      "span_granularity": "paragraph",
      "p_entail": 0.8602216243743896,
      "p_contr": 0.011250229552388191,
      "p_neut": 0.12852811813354492,
      "NLIScore": 0.8489713948220015
    },
    {
      "doc_id": "NCT01827163",
      "section": "Eligibility",
      "claim_id": "352475ea-1b17-4d1a-a5e3-71f1b87cffd8",
      "claim_text": "Any patients with histologically confirmed stage 4 adenocarcinoma HER2/neu immunohistochemistry 3+, ECOG performance status <2 and a Negative HCG pregnancy test are eligible for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  If patients have peripheral neuropathy, it must be  grade 1.   Patients must be willing to discontinue sex hormonal therapy e.g., birth control pills, ovarian hormonal replacement therapy, etc., prior to enrollment. Women of childbearing potential must be willing to consent to using effective contraception while on treatment and for a reasonable period thereafter.   Hematologic parameters: absolute neutrophil count (ANC) 1500/\u03bcL and platelet count 100,000/\u03bcL.   Non-hematologic parameters: total bilirubin must be  1.5 X institutional upper limit of normal (ULN), transaminases (SGOT or SGPT)  3.0 x ULN.   Negative HCG pregnancy test for premenopausal women of reproductive capacity and for women less than 12 months after the menopause. LVEF by ECHO (with strain if possible) with LVEF of  50%. If an ECHO cannot be done, a MUGA may be performed.",
      "span_granularity": "paragraph",
      "p_entail": 0.19840426743030548,
      "p_contr": 0.07400733977556229,
      "p_neut": 0.7275883555412292,
      "NLIScore": 0.1243969276547432
    },
    {
      "doc_id": "NCT00945061",
      "section": "Eligibility",
      "claim_id": "39227bbb-0e26-4ba0-94a7-762376541889",
      "claim_text": "Patients with Multi-focal breast cancer cannot be accepted for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Signed study-specific informed consent prior to study entry. Exclusion Criteria:   Patients with distant metastatic disease   Patients with invasive lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ (spanning more than 3 cm), or nonepithelial breast malignancies such as lymphoma or sarcoma.   Patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically or cytologically confirmed negative.",
      "span_granularity": "paragraph",
      "p_entail": 0.6331682205200195,
      "p_contr": 0.04233558475971222,
      "p_neut": 0.32449623942375183,
      "NLIScore": 0.5908326357603073
    },
    {
      "doc_id": "NCT00945061",
      "section": "Eligibility",
      "claim_id": "ee85e355-3d0a-4e40-8a8d-6a0b71c77148",
      "claim_text": "Patients with Multicentric breast cancer can be accepted for the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Lesion size  3 cm treated with a tylectomy and whole breast irradiation (with or without tumor bed boost)   Unifocal breast cancer recurrence   Negative resection margins with at least a 2 mm margin from invasive and in situ cancer or a negative re-excision   Hormonal therapy is allowed. If chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following completion of radiation.   Signed study-specific informed consent prior to study entry.",
      "span_granularity": "paragraph",
      "p_entail": 0.2690357565879822,
      "p_contr": 0.16864360868930817,
      "p_neut": 0.5623206496238708,
      "NLIScore": 0.10039214789867401
    },
    {
      "doc_id": "NCT01004744",
      "section": "Eligibility",
      "claim_id": "b02f43d7-44bb-4219-9a08-fd70e7cc9b87",
      "claim_text": "Patients must have a confirmed Postmenopausal status, defined as a lack of menses for over a year, if they are to take part in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Inclusion Criteria:   Histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or ductal carcinoma in situ (DCIS), who undergo core needle biopsy followed by surgical excision at least 2 weeks after enrollment   Postmenopausal status defined as cessation of menses for >1 year or FSH > 20 mIU/mL (within the past month)   Age  21 years   No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry",
      "span_granularity": "paragraph",
      "p_entail": 0.4845774173736572,
      "p_contr": 0.0037515207659453154,
      "p_neut": 0.5116710662841797,
      "NLIScore": 0.4808258966077119
    },
    {
      "doc_id": "NCT01004744",
      "section": "Eligibility",
      "claim_id": "2c602b4d-c8a5-4606-8e3a-a87ee7bbc480",
      "claim_text": "Patients must have a confirmed pregnancy by positive Hcg test, if they are to take part in the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "Inclusion Criteria:",
      "span_granularity": "sentence",
      "p_entail": 0.02260947972536087,
      "p_contr": 0.04762466996908188,
      "p_neut": 0.9297658801078796,
      "NLIScore": -0.02501519024372101
    },
    {
      "doc_id": "NCT00635050",
      "section": "Eligibility",
      "claim_id": "a5af6d2b-4cea-40aa-acdc-59fab5362b3e",
      "claim_text": "Patients with Breast cancers that have estrogen receptors are included in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Inclusion Criteria:",
      "span_granularity": "sentence",
      "p_entail": 0.10279461741447449,
      "p_contr": 0.030245810747146606,
      "p_neut": 0.8669595718383789,
      "NLIScore": 0.07254880666732788
    },
    {
      "doc_id": "NCT00635050",
      "section": "Eligibility",
      "claim_id": "0359eef3-6339-485e-95bc-0cb6fa7bcd12",
      "claim_text": "Patients with Breast cancers that have estrogen receptors are excluded from the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Patients with node-negative, ER or PR-positive tumors 4 cm in size whose tumors are low risk (defined as a score of 0-17) on an Oncotype DX profile are not eligible.   19 years of age or greater   Known ER, PR and HER-2 status (FISH assay to be done on specimens with 2+ or 3+ immunohistochemical staining for HER-2): patients with gene amplification on FISH study will be considered to be HER-2 positive. Patients for this study must be FISH negative if immunohistochemical stain is 2+ or 3+ positive; patients with negative, 0 or 1+ immunohistochemical stain for HER-2 are eligible.   Known axillary nodal status: aspiration cytology or biopsy   Documented menopausal status premenopausal (having menstrual periods or FSH <35) or postmenopausal (  12 months since last menstrual period with intact uterus and at least one ovary or FSH 35 or previous bilateral oophorectomy",
      "span_granularity": "paragraph",
      "p_entail": 0.2848854959011078,
      "p_contr": 0.07800569385290146,
      "p_neut": 0.6371088027954102,
      "NLIScore": 0.20687980204820633
    },
    {
      "doc_id": "NCT01466972",
      "section": "Adverse Events",
      "claim_id": "90cecb95-9f89-4747-81c3-96545edaf3f4",
      "claim_text": "No two patients in the primary trial suffered the same type of adverse event.",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Total: 8/30 (26.67%)",
      "span_granularity": "sentence",
      "p_entail": 0.04433388262987137,
      "p_contr": 0.15542739629745483,
      "p_neut": 0.8002387285232544,
      "NLIScore": -0.11109351366758347
    },
    {
      "doc_id": "NCT01466972",
      "section": "Adverse Events",
      "claim_id": "4bc60955-6137-4496-b780-5fb8e90dc3ed",
      "claim_text": "maculo-papular Rash was a common adverse event for the primary trial participants.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Adverse Events 1:   Total: 8/30 (26.67%)   Heart Failure 1/30 (3.33%)   Vertigo 1/30 (3.33%)   Small intestinal obstruction 1/30 (3.33%)   Fever 1/30 (3.33%)   Aspartate aminotransferase increased 1/30 (3.33%)   Alanine aminotransferase increased 1/30 (3.33%)   Back Pain 1/30 (3.33%)   Pleural effusion 1/30 (3.33%)   Rash maculo-papular 1/30 (3.33%)   Hypotension 1/30 (3.33%)",
      "span_granularity": "full-document",
      "p_entail": 0.03996361792087555,
      "p_contr": 0.005541988182812929,
      "p_neut": 0.9544943571090698,
      "NLIScore": 0.03442162973806262
    },
    {
      "doc_id": "NCT01466972",
      "section": "Adverse Events",
      "claim_id": "90cecb95-9f89-4747-81c3-96545edaf3f4",
      "claim_text": "No two patients in the primary trial suffered the same type of adverse event.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Total: 8/30 (26.67%)",
      "span_granularity": "sentence",
      "p_entail": 0.04433388262987137,
      "p_contr": 0.15542739629745483,
      "p_neut": 0.8002387285232544,
      "NLIScore": -0.11109351366758347
    },
    {
      "doc_id": "NCT01466972",
      "section": "Adverse Events",
      "claim_id": "4bc60955-6137-4496-b780-5fb8e90dc3ed",
      "claim_text": "Maculo-papular Rash was a common adverse event for the primary trial participants.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 8/30 (26.67%)   Heart Failure 1/30 (3.33%)   Vertigo 1/30 (3.33%)   Small intestinal obstruction 1/30 (3.33%)   Fever 1/30 (3.33%)   Aspartate aminotransferase increased 1/30 (3.33%)   Alanine aminotransferase increased 1/30 (3.33%)   Back Pain 1/30 (3.33%)   Pleural effusion 1/30 (3.33%)   Rash maculo-papular 1/30 (3.33%)   Hypotension 1/30 (3.33%)",
      "span_granularity": "full-document",
      "p_entail": 0.04195679351687431,
      "p_contr": 0.004843416623771191,
      "p_neut": 0.9531998038291931,
      "NLIScore": 0.03711337689310312
    },
    {
      "doc_id": "NCT02370238",
      "section": "Adverse Events",
      "claim_id": "a847cfc1-9556-4a55-9698-69c22696148f",
      "claim_text": "There were 2 cases of Angina in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Stomatitis 0/61 (0.00%)   Non-cardiac chest pain 2/61 (3.28%)   Condition aggravated 1/61 (1.64%)   General physical health deterioration 1/61 (1.64%) Adverse Events 2:",
      "span_granularity": "paragraph",
      "p_entail": 0.09706583619117737,
      "p_contr": 0.06217543035745621,
      "p_neut": 0.840758740901947,
      "NLIScore": 0.03489040583372116
    },
    {
      "doc_id": "NCT02370238",
      "section": "Adverse Events",
      "claim_id": "9dbf55d5-6af3-4250-b5cb-97799cdf778a",
      "claim_text": "There were no cases of Intracranial hemorrhage in the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Non-cardiac chest pain 0/60 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.017508134245872498,
      "p_contr": 0.5836840867996216,
      "p_neut": 0.3988077640533447,
      "NLIScore": -0.5661759525537491
    },
    {
      "doc_id": "NCT02370238",
      "section": "Adverse Events",
      "claim_id": "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7",
      "claim_text": "There were more total AEs in cohort 1 of the primary trial than cohort 2",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 13/61 (21.31%)   Anaemia 1/61 (1.64%)   Febrile neutropenia 1/61 (1.64%)   Cardiac failure congestive 0/61 (0.00%)   Pericardial effusion 0/61 (0.00%)   Constipation 1/61 (1.64%)   Intestinal perforation 1/61 (1.64%)   Stomatitis 0/61 (0.00%)   Non-cardiac chest pain 2/61 (3.28%)   Condition aggravated 1/61 (1.64%)   General physical health deterioration 1/61 (1.64%) Adverse Events 2:   Total: 12/60 (20.00%)   Anaemia 1/60 (1.67%)   Febrile neutropenia 0/60 (0.00%)   Cardiac failure congestive 1/60 (1.67%)   Pericardial effusion 1/60 (1.67%)   Constipation 0/60 (0.00%)   Intestinal perforation 0/60 (0.00%)   Stomatitis 1/60 (1.67%)   Non-cardiac chest pain 0/60 (0.00%)   Condition aggravated 0/60 (0.00%)   General physical health deterioration 1/60 (1.67%)",
      "span_granularity": "full-document",
      "p_entail": 0.18315532803535461,
      "p_contr": 0.04870549216866493,
      "p_neut": 0.7681392431259155,
      "NLIScore": 0.13444983586668968
    },
    {
      "doc_id": "NCT02370238",
      "section": "Adverse Events",
      "claim_id": "2da13cd4-7189-4f85-be4d-5c1e213ae293",
      "claim_text": "The most common AE in the primary trial was Non-cardiac chest pain, which affected less than 5% of participants in cohort 1.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Constipation 1/61 (1.64%)   Intestinal perforation 1/61 (1.64%)   Stomatitis 0/61 (0.00%)   Non-cardiac chest pain 2/61 (3.28%)   Condition aggravated 1/61 (1.64%)",
      "span_granularity": "paragraph",
      "p_entail": 0.09925926476716995,
      "p_contr": 0.04169778153300285,
      "p_neut": 0.8590430021286011,
      "NLIScore": 0.0575614832341671
    },
    {
      "doc_id": "NCT00670982",
      "section": "Adverse Events",
      "claim_id": "f40c8d92-2921-45fd-8389-15048b08e229",
      "claim_text": "Neutropenia was the most prevalent adverse event in the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 2:",
      "span_granularity": "sentence",
      "p_entail": 0.0007035356829874218,
      "p_contr": 0.004271335434168577,
      "p_neut": 0.995025098323822,
      "NLIScore": -0.0035677997511811554
    },
    {
      "doc_id": "NCT00670982",
      "section": "Adverse Events",
      "claim_id": "d56745c3-ba0b-4b42-b3cf-ac060f658d83",
      "claim_text": "Acute coronary syndrome was the most prevalent adverse event in the primary trial, other than Thrombocytopenia.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "   ",
      "span_granularity": "sentence",
      "p_entail": 0.02107301354408264,
      "p_contr": 0.02128811925649643,
      "p_neut": 0.9576388597488403,
      "NLIScore": -0.00021510571241378784
    },
    {
      "doc_id": "NCT00448591",
      "section": "Adverse Events",
      "claim_id": "78c60212-28f7-4306-9f63-549be04687b2",
      "claim_text": "Only two types of adverse events, Leukopenia and Anaemia, occurred in more than 1% of patients in cohort 1 of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 672/2264 (29.68%)   Febrile neutropenia * 117/2264 (5.17%)   Neutropenia * 98/2264 (4.33%)   Febrile bone marrow aplasia * 14/2264 (0.62%)   Anaemia * 8/2264 (0.35%)   Leukopenia * 8/2264 (0.35%)   Thrombocytopenia * 6/2264 (0.27%)   Disseminated intravascular coagulation * 3/2264 (0.13%)   Agranulocytosis * 1/2264 (0.04%)   Bone marrow failure * 1/2264 (0.04%)",
      "span_granularity": "full-document",
      "p_entail": 0.3255864679813385,
      "p_contr": 0.077814981341362,
      "p_neut": 0.5965985655784607,
      "NLIScore": 0.2477714866399765
    },
    {
      "doc_id": "NCT00448591",
      "section": "Adverse Events",
      "claim_id": "f7410166-82a7-4d15-8a04-47287ef6884c",
      "claim_text": "Only two types of adverse events occurred in more than 1% of patients in cohort 1 of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 672/2264 (29.68%)   Febrile neutropenia * 117/2264 (5.17%)   Neutropenia * 98/2264 (4.33%)   Febrile bone marrow aplasia * 14/2264 (0.62%)   Anaemia * 8/2264 (0.35%)   Leukopenia * 8/2264 (0.35%)   Thrombocytopenia * 6/2264 (0.27%)   Disseminated intravascular coagulation * 3/2264 (0.13%)   Agranulocytosis * 1/2264 (0.04%)   Bone marrow failure * 1/2264 (0.04%)",
      "span_granularity": "full-document",
      "p_entail": 0.3127242624759674,
      "p_contr": 0.02223622240126133,
      "p_neut": 0.6650394797325134,
      "NLIScore": 0.2904880400747061
    },
    {
      "doc_id": "NCT01250379",
      "section": "Adverse Events",
      "claim_id": "8f5423c9-17b5-4f66-aa9f-1fc9763958b2",
      "claim_text": "None of the patients in the primary trial had Thrombocytopenia, heart failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Acute coronary syndrome * 0/238 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.0029823887161910534,
      "p_contr": 0.9221013784408569,
      "p_neut": 0.07491620630025864,
      "NLIScore": -0.9191189897246659
    },
    {
      "doc_id": "NCT01250379",
      "section": "Adverse Events",
      "claim_id": "6c57e451-a706-4b32-ae71-254e9d0e04de",
      "claim_text": "None of the patients in the primary trial had Thrombocytopenia, congestive Cardiac failure, Pancytopenia, Acute coronary syndrome or Atrial fibrillation.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Cardiac failure congestive * 0/238 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.0027205145452171564,
      "p_contr": 0.9117229580879211,
      "p_neut": 0.0855565220117569,
      "NLIScore": -0.909002443542704
    },
    {
      "doc_id": "NCT02291913",
      "section": "Adverse Events",
      "claim_id": "9a31db67-e28a-4114-a308-e899f9c22813",
      "claim_text": "One patient in the primary trial suffered from an inflammation of the esophagus.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 15/48 (31.25%)   Anemia * 1/48 (2.08%)   Cardiac failure congestive * 1/48 (2.08%)   Constipation * 2/48 (4.17%)   Esophagitis * 1/48 (2.08%)   Gastrointestinal hemorrhage * 1/48 (2.08%)   Non-Cardiac chest pain * 1/48 (2.08%)   Pain * 1/48 (2.08%)   Cholecystitis * 1/48 (2.08%)   Diverticulitis * 1/48 (2.08%)   Cellulitis * 1/48 (2.08%)   Gastroenteritis * 1/48 (2.08%)",
      "span_granularity": "full-document",
      "p_entail": 0.8204155564308167,
      "p_contr": 0.005123603623360395,
      "p_neut": 0.17446082830429077,
      "NLIScore": 0.8152919528074563
    },
    {
      "doc_id": "NCT02291913",
      "section": "Adverse Events",
      "claim_id": "5cf74526-9f91-498d-a13a-6393dcd45b7b",
      "claim_text": "One patient in the primary trial suffered from an inflammation of the liver.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Gastroenteritis * 1/48 (2.08%)",
      "span_granularity": "sentence",
      "p_entail": 0.6417829394340515,
      "p_contr": 0.004698228091001511,
      "p_neut": 0.35351884365081787,
      "NLIScore": 0.63708471134305
    },
    {
      "doc_id": "NCT03384316",
      "section": "Adverse Events",
      "claim_id": "44412911-1f34-4841-a795-86eed5a209d7",
      "claim_text": "All Infections and Fever cases in the primary trial were for patients in cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.004243313800543547,
      "p_contr": 0.018225401639938354,
      "p_neut": 0.9775312542915344,
      "NLIScore": -0.013982087839394808
    },
    {
      "doc_id": "NCT03384316",
      "section": "Adverse Events",
      "claim_id": "d9d506ef-20ed-44e2-9809-07cb0772535b",
      "claim_text": "All Infections and Infestations cases in the primary trial were for patients in cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.0069704605266451836,
      "p_contr": 0.030660975724458694,
      "p_neut": 0.9623686075210571,
      "NLIScore": -0.02369051519781351
    },
    {
      "doc_id": "NCT03384316",
      "section": "Adverse Events",
      "claim_id": "44412911-1f34-4841-a795-86eed5a209d7",
      "claim_text": "All Infections and Fever cases in the primary trial were for patients in cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.004243313800543547,
      "p_contr": 0.018225401639938354,
      "p_neut": 0.9775312542915344,
      "NLIScore": -0.013982087839394808
    },
    {
      "doc_id": "NCT03384316",
      "section": "Adverse Events",
      "claim_id": "d9d506ef-20ed-44e2-9809-07cb0772535b",
      "claim_text": "All Infections and Infestations cases in the primary trial were for patients in cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.0069704605266451836,
      "p_contr": 0.030660975724458694,
      "p_neut": 0.9623686075210571,
      "NLIScore": -0.02369051519781351
    },
    {
      "doc_id": "NCT00567190",
      "section": "Adverse Events",
      "claim_id": "4fa6b99e-0e70-465d-8b24-b728979b3689",
      "claim_text": "There was the same number of anemic patients in both cohorts of the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Leukopenia 0/408 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.005864379927515984,
      "p_contr": 0.17041487991809845,
      "p_neut": 0.8237207531929016,
      "NLIScore": -0.16455049999058247
    },
    {
      "doc_id": "NCT00567190",
      "section": "Adverse Events",
      "claim_id": "87eca8d2-72fe-4285-9884-6d2ec7bae6df",
      "claim_text": "There was exactly the same proportion of anemic patients in both cohorts of the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Leukopenia 0/408 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.007781328167766333,
      "p_contr": 0.14421439170837402,
      "p_neut": 0.8480043411254883,
      "NLIScore": -0.1364330635406077
    },
    {
      "doc_id": "NCT00320541",
      "section": "Adverse Events",
      "claim_id": "5b1915da-1819-4504-81bd-3f44a83b5e95",
      "claim_text": "Cohort 2 of the primary trial recorded three times as many cases of Leukopenia as cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 2:",
      "span_granularity": "sentence",
      "p_entail": 0.012231740169227123,
      "p_contr": 0.022024840116500854,
      "p_neut": 0.9657434821128845,
      "NLIScore": -0.009793099947273731
    },
    {
      "doc_id": "NCT00320541",
      "section": "Adverse Events",
      "claim_id": "d9236874-7f3d-4402-9699-2889db9f5c61",
      "claim_text": "Cohort 2 of the primary trial recorded 10% more cases of Leukopenia than cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 2:",
      "span_granularity": "sentence",
      "p_entail": 0.02101300284266472,
      "p_contr": 0.024442158639431,
      "p_neut": 0.9545448422431946,
      "NLIScore": -0.003429155796766281
    },
    {
      "doc_id": "NCT00468585",
      "section": "Adverse Events",
      "claim_id": "a2b25229-c003-49c3-8b0b-94b68f756d3c",
      "claim_text": "the primary trial did not record any skin infections in their patients.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Total: 0/3 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.06632302701473236,
      "p_contr": 0.24232585728168488,
      "p_neut": 0.6913511157035828,
      "NLIScore": -0.17600283026695251
    },
    {
      "doc_id": "NCT00468585",
      "section": "Adverse Events",
      "claim_id": "276f5523-f45b-45b0-ad30-b737f2c1b1d0",
      "claim_text": "the primary trial recorded several skin infections in their patients.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 2/4 (50.00%)   Atrial fibrillation 0/4 (0.00%)   Dehydration 1/4 (25.00%)   Fatigue (asthenia, lethargy, malaise) 1/4 (25.00%)   Pain - Back 1/4 (25.00%)   Urinary tract infection 0/4 (0.00%)   Dyspnea (shortness of breath) 0/4 (0.00%)   Pericardial effusion 0/4 (0.00%)   Thrombosis 0/4 (0.00%)   Skin infection 0/4 (0.00%)   Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2:   Total: 0/3 (0.00%)   Atrial fibrillation 0/3 (0.00%)   Dehydration 0/3 (0.00%)   Fatigue (asthenia, lethargy, malaise) 0/3 (0.00%)   Pain - Back 0/3 (0.00%)   Urinary tract infection 0/3 (0.00%)   Dyspnea (shortness of breath) 0/3 (0.00%)   Pericardial effusion 0/3 (0.00%)   Thrombosis 0/3 (0.00%)   Skin infection 0/3 (0.00%)   Rash: hand-foot skin reaction 0/3 (0.00%)",
      "span_granularity": "full-document",
      "p_entail": 0.24100619554519653,
      "p_contr": 0.0062842899933457375,
      "p_neut": 0.7527094483375549,
      "NLIScore": 0.2347219055518508
    },
    {
      "doc_id": "NCT01998906",
      "section": "Adverse Events",
      "claim_id": "2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25",
      "claim_text": "The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 18/115 (15.65%)   Febrile neutropenia * 7/115 (6.09%)   Neutropenia * 1/115 (0.87%)   Pancytopenia * 1/115 (0.87%)",
      "span_granularity": "paragraph",
      "p_entail": 0.1363668441772461,
      "p_contr": 0.10762426257133484,
      "p_neut": 0.7560088038444519,
      "NLIScore": 0.028742581605911255
    },
    {
      "doc_id": "NCT01998906",
      "section": "Adverse Events",
      "claim_id": "2417fea2-7c8e-4f03-a918-c3cfcbe97425",
      "claim_text": "The same number of cases of Neutropenia, Febrile neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 18/115 (15.65%)   Febrile neutropenia * 7/115 (6.09%)   Neutropenia * 1/115 (0.87%)   Pancytopenia * 1/115 (0.87%)",
      "span_granularity": "paragraph",
      "p_entail": 0.15488354861736298,
      "p_contr": 0.1101967990398407,
      "p_neut": 0.7349197268486023,
      "NLIScore": 0.04468674957752228
    },
    {
      "doc_id": "NCT00391092",
      "section": "Adverse Events",
      "claim_id": "1a451f2e-0818-4a86-8808-0e4cce700aef",
      "claim_text": "In total there were 32 cases of Febrile neutropenia in the primary trial, and only one case of anemia.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 63/206 (30.58%)   Febrile neutropenia * 14/206 (6.80%)   Neutropenia * 9/206 (4.37%)   Anaemia * 1/206 (0.49%)",
      "span_granularity": "paragraph",
      "p_entail": 0.7772447466850281,
      "p_contr": 0.11864235252141953,
      "p_neut": 0.10411297529935837,
      "NLIScore": 0.6586023941636086
    },
    {
      "doc_id": "NCT00391092",
      "section": "Adverse Events",
      "claim_id": "fa1c6f63-ae37-4c18-918b-7b9ba445fd81",
      "claim_text": "In total there were 32 cases of Febrile neutropenia in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Febrile neutropenia * 18/215 (8.37%)   Neutropenia * 6/215 (2.79%)   Anaemia * 1/215 (0.47%)   Leukopenia * 1/215 (0.47%)   Thrombocytopenia * 0/215 (0.00%)",
      "span_granularity": "paragraph",
      "p_entail": 0.2578478753566742,
      "p_contr": 0.04995247721672058,
      "p_neut": 0.6921996474266052,
      "NLIScore": 0.2078953981399536
    },
    {
      "doc_id": "NCT00930930",
      "section": "Adverse Events",
      "claim_id": "79dbf7bf-e08d-4eae-a804-0daeb83d6f01",
      "claim_text": "The most frequent adverse event in cohort 1 of the primary trial was lymphopenia.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 22/96 (22.92%)   Anemia 1/96 (1.04%)   lymphopenia 1/96 (1.04%)   cardiac ischemia/infarction 1/96 (1.04%)",
      "span_granularity": "paragraph",
      "p_entail": 0.1930839717388153,
      "p_contr": 0.008424212224781513,
      "p_neut": 0.7984918355941772,
      "NLIScore": 0.1846597595140338
    },
    {
      "doc_id": "NCT00930930",
      "section": "Adverse Events",
      "claim_id": "81669281-db01-4493-a797-0d60f448f706",
      "claim_text": "The overall most frequent adverse event in the primary trial was Dehydration.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Anemia 0/49 (0.00%)   lymphopenia 0/49 (0.00%)   cardiac ischemia/infarction 0/49 (0.00%)   sinus tachycardia 0/49 (0.00%)   Dehydration 1/49 (2.04%)",
      "span_granularity": "paragraph",
      "p_entail": 0.16610084474086761,
      "p_contr": 0.004183038137853146,
      "p_neut": 0.829716145992279,
      "NLIScore": 0.16191780660301447
    },
    {
      "doc_id": "NCT02630693",
      "section": "Adverse Events",
      "claim_id": "21cf4dfe-2cd7-4e60-943d-2f7e1266a80d",
      "claim_text": "A 30% of patients in the primary trial suffered a life-threatening reaction to an infection.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Other hepatobiliary disorders 1/90 (1.11%)   Lung infection 2/90 (2.22%)   Sepsis 2/90 (2.22%)   Spinal fracture 0/90 (0.00%) Adverse Events 2:",
      "span_granularity": "paragraph",
      "p_entail": 0.4747394621372223,
      "p_contr": 0.019647374749183655,
      "p_neut": 0.5056130886077881,
      "NLIScore": 0.45509208738803864
    },
    {
      "doc_id": "NCT02630693",
      "section": "Adverse Events",
      "claim_id": "efd37946-54f3-4813-b63d-6d7df6123677",
      "claim_text": "A total of 3 patients in the primary trial suffered a life-threatening reaction to an infection.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Spinal fracture 0/90 (0.00%) Adverse Events 2:   Total: 12/89 (13.48%)   Febrile neutropenia 0/89 (0.00%)   Ascites 1/89 (1.12%)",
      "span_granularity": "paragraph",
      "p_entail": 0.5804168581962585,
      "p_contr": 0.02191889099776745,
      "p_neut": 0.39766424894332886,
      "NLIScore": 0.5584979671984911
    },
    {
      "doc_id": "NCT00934856",
      "section": "Adverse Events",
      "claim_id": "348c9273-6aa1-43a8-840d-3cf080874669",
      "claim_text": "In total, across both cohorts of the primary trial, there were at least 2 patients with a fever.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Hepatocellular injury * 1/6 (16.67%)   Cholecystitis * 1/6 (16.67%) Adverse Events 2:   Total: 2/6 (33.33%)   Febrile neutropenia * 1/6 (16.67%)",
      "span_granularity": "paragraph",
      "p_entail": 0.3436935245990753,
      "p_contr": 0.0058636292815208435,
      "p_neut": 0.6504428386688232,
      "NLIScore": 0.3378298953175545
    },
    {
      "doc_id": "NCT00934856",
      "section": "Adverse Events",
      "claim_id": "60bff573-0251-4f05-b2b7-dec74c7363cc",
      "claim_text": "In total, across both cohorts of the primary trial, there was at least 2 fatigued patients.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Hepatocellular injury * 1/6 (16.67%)   Cholecystitis * 1/6 (16.67%) Adverse Events 2:   Total: 2/6 (33.33%)   Febrile neutropenia * 1/6 (16.67%)",
      "span_granularity": "paragraph",
      "p_entail": 0.25973787903785706,
      "p_contr": 0.0053193578496575356,
      "p_neut": 0.7349428534507751,
      "NLIScore": 0.2544185211881995
    },
    {
      "doc_id": "NCT00917735",
      "section": "Adverse Events",
      "claim_id": "b86f0f3c-7905-470d-ae5d-e1867eb8bd3b",
      "claim_text": "One patient in cohort 2 of the primary trial crashed their motorbike.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Diagnosis of Uterine Cancer 0/538 (0.00%)   Motorcycle accident 0/538 (0.00%)   Fall 0/538 (0.00%)   Surgery 3/538 (0.56%) Adverse Events 2:",
      "span_granularity": "paragraph",
      "p_entail": 0.6182690858840942,
      "p_contr": 0.02034568600356579,
      "p_neut": 0.3613852262496948,
      "NLIScore": 0.5979233998805285
    },
    {
      "doc_id": "NCT00917735",
      "section": "Adverse Events",
      "claim_id": "deb77d34-76a5-4e6e-bc9d-176cc30eca07",
      "claim_text": "One patient in cohort 2 of the primary trial died in a motorcycle crash.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Colitis 0/537 (0.00%)   Elevated ALT or AST enzyme 0/537 (0.00%)   Diagnosis of Uterine Cancer 2/537 (0.37%)   Motorcycle accident 1/537 (0.19%)   Fall 1/537 (0.19%)",
      "span_granularity": "paragraph",
      "p_entail": 0.5082783699035645,
      "p_contr": 0.004517782013863325,
      "p_neut": 0.48720383644104004,
      "NLIScore": 0.5037605878897011
    },
    {
      "doc_id": "NCT00203502",
      "section": "Adverse Events",
      "claim_id": "4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37",
      "claim_text": "Every single patient in the primary trial experienced at least 1 adverse event.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 39/39 (100.00%)   Febrile Neutropenia  1/39 (2.56%)   Heart failure  1/39 (2.56%)   Diarrhea  3/39 (7.69%)   Nausea/vomiting  4/39 (10.26%)   Mucositis  3/39 (7.69%)   Fatigue  4/39 (10.26%)   infection  3/39 (7.69%)   Urinary tract infection  2/39 (5.13%)   Musculoskeletal pain  6/39 (15.38%)   Syncope  1/39 (2.56%)   Insomnia  3/39 (7.69%)   Anxiety  2/39 (5.13%)",
      "span_granularity": "full-document",
      "p_entail": 0.4009902775287628,
      "p_contr": 0.018025996163487434,
      "p_neut": 0.5809836983680725,
      "NLIScore": 0.3829642813652754
    },
    {
      "doc_id": "NCT00203502",
      "section": "Adverse Events",
      "claim_id": "619d88fd-cef5-4f1a-83dc-3cc710c1c93d",
      "claim_text": "Less than 30% of patients in the primary trial experienced at least 1 adverse event.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Total: 39/39 (100.00%)   Febrile Neutropenia  1/39 (2.56%)   Heart failure  1/39 (2.56%)   Diarrhea  3/39 (7.69%)   Nausea/vomiting  4/39 (10.26%)",
      "span_granularity": "paragraph",
      "p_entail": 0.6896181702613831,
      "p_contr": 0.0937068983912468,
      "p_neut": 0.21667489409446716,
      "NLIScore": 0.5959112718701363
    },
    {
      "doc_id": "NCT00328783",
      "section": "Adverse Events",
      "claim_id": "97fd111c-6969-43ab-93af-b3dff09960e5",
      "claim_text": "The adverse events section in the primary trial reports the incidence rate of 12 different adverse events.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Total: 0/0",
      "span_granularity": "sentence",
      "p_entail": 0.13369929790496826,
      "p_contr": 0.16714876890182495,
      "p_neut": 0.6991519927978516,
      "NLIScore": -0.03344947099685669
    },
    {
      "doc_id": "NCT00328783",
      "section": "Adverse Events",
      "claim_id": "fef5aedb-21c0-4130-b8a3-cb1df5017c7a",
      "claim_text": "The adverse events section in the primary trial is empty",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 0/0",
      "span_granularity": "full-document",
      "p_entail": 0.12150474637746811,
      "p_contr": 0.009967194870114326,
      "p_neut": 0.8685280680656433,
      "NLIScore": 0.11153755150735378
    },
    {
      "doc_id": "NCT01644890",
      "section": "Adverse Events",
      "claim_id": "7d22937b-9823-45fa-a914-261f993e4d64",
      "claim_text": "Throughout the primary trial, one patient developed issues with their vision.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Macular fibrosis 1/213 (0.47%)",
      "span_granularity": "sentence",
      "p_entail": 0.6784791946411133,
      "p_contr": 0.0020005174446851015,
      "p_neut": 0.31952032446861267,
      "NLIScore": 0.6764786771964282
    },
    {
      "doc_id": "NCT01644890",
      "section": "Adverse Events",
      "claim_id": "3129e58d-0c16-42a5-90b4-f26e048dfe58",
      "claim_text": "Throughout the primary trial, one patient in cohort 1 developed issues with their vision.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Enterocolitis 1/213 (0.47%)",
      "span_granularity": "sentence",
      "p_entail": 0.5577833652496338,
      "p_contr": 0.008007582277059555,
      "p_neut": 0.43420904874801636,
      "NLIScore": 0.5497757829725742
    },
    {
      "doc_id": "NCT00587964",
      "section": "Adverse Events",
      "claim_id": "412583db-ce19-451d-a804-3837e4dcaea3",
      "claim_text": "Coronary artery stenosis are the most common AE recorded in the primary trial",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.00258226809091866,
      "p_contr": 0.013532117940485477,
      "p_neut": 0.983885645866394,
      "NLIScore": -0.010949849849566817
    },
    {
      "doc_id": "NCT00587964",
      "section": "Adverse Events",
      "claim_id": "05530068-7a95-46f6-88d2-84e53ee2ff35",
      "claim_text": "General symptoms are the most common AE recorded in the primary trial",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  Vision-blurred vision 1/51 (1.96%)   Constipation 1/51 (1.96%)   Radiation oesophagitis 1/51 (1.96%)   Nausea 2/51 (3.92%)   Vomiting 2/51 (3.92%)",
      "span_granularity": "paragraph",
      "p_entail": 0.030680907890200615,
      "p_contr": 0.006176483817398548,
      "p_neut": 0.9631425738334656,
      "NLIScore": 0.024504424072802067
    },
    {
      "doc_id": "NCT00587964",
      "section": "Adverse Events",
      "claim_id": "412583db-ce19-451d-a804-3837e4dcaea3",
      "claim_text": "Coronary artery stenosis is the most common adverse event recorded in the primary trial",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Thrombosis 1/51 (1.96%)",
      "span_granularity": "sentence",
      "p_entail": 0.013797487132251263,
      "p_contr": 0.015689576044678688,
      "p_neut": 0.9705130457878113,
      "NLIScore": -0.0018920889124274254
    },
    {
      "doc_id": "NCT00587964",
      "section": "Adverse Events",
      "claim_id": "05530068-7a95-46f6-88d2-84e53ee2ff35",
      "claim_text": "General symptoms are the most common adverse events recorded in the primary trial",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 16/51 (31.37%)   Blood disorder 1/51 (1.96%)   Hypomagnesemia 1/51 (1.96%)   Platelets count decrease 1/51 (1.96%)",
      "span_granularity": "paragraph",
      "p_entail": 0.08618825674057007,
      "p_contr": 0.00906192697584629,
      "p_neut": 0.9047498106956482,
      "NLIScore": 0.07712632976472378
    },
    {
      "doc_id": "NCT00820872",
      "section": "Adverse Events",
      "claim_id": "ed43519d-9954-4e0f-9d42-39a3ed81e4a5",
      "claim_text": "Hyperglycemia was the most common adverse event in cohort 1 of the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.0008951075724326074,
      "p_contr": 0.002981301164254546,
      "p_neut": 0.9961236119270325,
      "NLIScore": -0.0020861935918219388
    },
    {
      "doc_id": "NCT00820872",
      "section": "Adverse Events",
      "claim_id": "92acd36d-ea44-4b98-acbc-e51382233089",
      "claim_text": "Diarrhea was the most common adverse event in cohort 1 of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 10/30 (33.33%)   Hemoglobin decreased 2/30 (6.67%)   Abdominal pain 1/30 (3.33%)   Colitis 1/30 (3.33%)   Diarrhea 7/30 (23.33%)   Nausea 2/30 (6.67%)   Rectal hemorrhage 1/30 (3.33%)   Fatigue 1/30 (3.33%)   Skin infection 1/30 (3.33%)   Neutrophil count decreased 1/30 (3.33%)   Platelet count decreased 3/30 (10.00%)   Dehydration 1/30 (3.33%)",
      "span_granularity": "full-document",
      "p_entail": 0.06542837619781494,
      "p_contr": 0.01257768739014864,
      "p_neut": 0.9219939708709717,
      "NLIScore": 0.0528506888076663
    },
    {
      "doc_id": "NCT00206427",
      "section": "Adverse Events",
      "claim_id": "611317e3-83f9-4e8d-9a9d-3dcda62fb6cb",
      "claim_text": "A patient in the primary trial had an oral fungal infection.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 3/49 (6.12%)   Neutrophils/ANC *1/49 (2.04%)   Leukocytes *1/49 (2.04%)   Hypocalcemia *1/49 (2.04%)   Febrile neutropenia *1/49 (2.04%)   Left Ventricular Systolic Dysfunction *1/49 (2.04%)   Constipation *1/49 (2.04%)   Mucositis-oral *1/49 (2.04%)   Infection-oral thrush *1/49 (2.04%)   rash *1/49 (2.04%)",
      "span_granularity": "full-document",
      "p_entail": 0.42466655373573303,
      "p_contr": 0.011814722791314125,
      "p_neut": 0.5635187029838562,
      "NLIScore": 0.4128518309444189
    },
    {
      "doc_id": "NCT00206427",
      "section": "Adverse Events",
      "claim_id": "a18c447b-de08-48ef-8e65-0ecaa775c2b0",
      "claim_text": "A patient in the primary trial had a vaginal fungal infection.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Total: 3/49 (6.12%)",
      "span_granularity": "sentence",
      "p_entail": 0.11870642006397247,
      "p_contr": 0.034391965717077255,
      "p_neut": 0.8469015955924988,
      "NLIScore": 0.08431445434689522
    },
    {
      "doc_id": "NCT01498458",
      "section": "Adverse Events",
      "claim_id": "53d88010-e7d7-41c7-b20d-6328c8e507d1",
      "claim_text": "For some adverse event types in the primary trial, there were no recorded cases.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Total: 6/8 (75.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.014262834563851357,
      "p_contr": 0.04831070452928543,
      "p_neut": 0.9374263882637024,
      "NLIScore": -0.034047869965434074
    },
    {
      "doc_id": "NCT01498458",
      "section": "Adverse Events",
      "claim_id": "d9e41be5-1e37-4dff-b51a-166576f351d0",
      "claim_text": "For all adverse event types in the primary trial, at least one case was recorded.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 6/8 (75.00%)   Thrombocytopenia 1/8 (12.50%)   Hypertension 1/8 (12.50%)   Hepatotoxicity 3/8 (37.50%)",
      "span_granularity": "paragraph",
      "p_entail": 0.5329309701919556,
      "p_contr": 0.010146092623472214,
      "p_neut": 0.4569230377674103,
      "NLIScore": 0.5227848775684834
    },
    {
      "doc_id": "NCT01498458",
      "section": "Adverse Events",
      "claim_id": "571d4650-e64b-4cb2-b719-0d7064e51745",
      "claim_text": "in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Hepatotoxicity 3/8 (37.50%)",
      "span_granularity": "sentence",
      "p_entail": 0.0009007601183839142,
      "p_contr": 0.012081134133040905,
      "p_neut": 0.9870180487632751,
      "NLIScore": -0.01118037401465699
    },
    {
      "doc_id": "NCT01498458",
      "section": "Adverse Events",
      "claim_id": "9d94e597-591d-409e-a8e2-b205a83533a5",
      "claim_text": "in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Hepatotoxicity 3/8 (37.50%)",
      "span_granularity": "sentence",
      "p_entail": 0.0008948607719503343,
      "p_contr": 0.006541436538100243,
      "p_neut": 0.9925636649131775,
      "NLIScore": -0.005646575766149908
    },
    {
      "doc_id": "NCT01498458",
      "section": "Adverse Events",
      "claim_id": "571d4650-e64b-4cb2-b719-0d7064e51745",
      "claim_text": "In the primary trial, there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Hepatotoxicity 3/8 (37.50%)",
      "span_granularity": "sentence",
      "p_entail": 0.0013859844766557217,
      "p_contr": 0.036211345344781876,
      "p_neut": 0.9624025821685791,
      "NLIScore": -0.034825360868126154
    },
    {
      "doc_id": "NCT01498458",
      "section": "Adverse Events",
      "claim_id": "9d94e597-591d-409e-a8e2-b205a83533a5",
      "claim_text": "In the primary trial, there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Hepatotoxicity 3/8 (37.50%)",
      "span_granularity": "sentence",
      "p_entail": 0.0013625010615214705,
      "p_contr": 0.018030835315585136,
      "p_neut": 0.9806066155433655,
      "NLIScore": -0.016668334254063666
    },
    {
      "doc_id": "NCT01120184",
      "section": "Adverse Events",
      "claim_id": "eb152d1b-a0d6-428c-8d1d-eb5d862a8147",
      "claim_text": "At least 1 patient in cohort 1 of the primary trial suffered from a Hemophilia, a rare coagulation disorder.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Febrile neutropenia * 13/353 (3.68%)",
      "span_granularity": "sentence",
      "p_entail": 0.39835840463638306,
      "p_contr": 0.11589369922876358,
      "p_neut": 0.48574790358543396,
      "NLIScore": 0.2824647054076195
    },
    {
      "doc_id": "NCT01120184",
      "section": "Adverse Events",
      "claim_id": "da00532d-57a8-4fe2-a2de-acc525161fd9",
      "claim_text": "At least 1 patient in cohort 1 of the primary trial suffered from a coagulation disorder.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 81/353 (22.95%)   Febrile neutropenia * 13/353 (3.68%)   Anaemia * 21/353 (0.28%)   Neutropenia * 25/353 (1.42%)   Thrombocytopenia * 20/353 (0.00%)   Hypercoagulation * 21/353 (0.28%)   Leukopenia * 21/353 (0.28%)   Atrial fibrillation * 1/353 (0.28%)   Cardiac failure * 0/353 (0.00%)   Cardiac failure congestive * 0/353 (0.00%)   Myocardial infarction * 1/353 (0.28%) Adverse Events 2:   Total: 86/361 (23.82%)   Febrile neutropenia * 0/361 (0.00%)   Anaemia * 25/361 (1.39%)   Neutropenia * 20/361 (0.00%)   Thrombocytopenia * 22/361 (0.55%)   Hypercoagulation * 20/361 (0.00%)   Leukopenia * 20/361 (0.00%)   Atrial fibrillation * 0/361 (0.00%)   Cardiac failure * 0/361 (0.00%)   Cardiac failure congestive * 0/361 (0.00%)   Myocardial infarction * 0/361 (0.00%)",
      "span_granularity": "full-document",
      "p_entail": 0.7975282669067383,
      "p_contr": 0.004165620543062687,
      "p_neut": 0.19830606877803802,
      "NLIScore": 0.7933626463636756
    },
    {
      "doc_id": "NCT01439282",
      "section": "Adverse Events",
      "claim_id": "20530faf-addb-47bf-896d-b9666e149223",
      "claim_text": "In total cohort 1 of the primary trial recorded 20% more adverse events than cohort 2.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 14/67 (20.90%)   Febrile neutropenia 21/67 (1.49%)   Leukopenia 21/67 (1.49%)   Neutropenia 21/67 (1.49%)   Macular hole 21/67 (1.49%)   Diarrhoea 22/67 (2.99%)   Abdominal pain 21/67 (1.49%)   Abdominal pain upper 21/67 (1.49%)   Enteritis 21/67 (1.49%)   Gastritis 21/67 (1.49%)   Nausea 21/67 (1.49%)   Vomiting 21/67 (1.49%)   Pneumonia 21/67 (1.49%) Adverse Events 2:   Total: 1/10 (10.00%)   Febrile neutropenia 20/10 (0.00%)   Leukopenia 20/10 (0.00%)   Neutropenia 20/10 (0.00%)   Macular hole 20/10 (0.00%)   Diarrhoea 20/10 (0.00%)   Abdominal pain 20/10 (0.00%)   Abdominal pain upper 20/10 (0.00%)   Enteritis 20/10 (0.00%)   Gastritis 20/10 (0.00%)   Nausea 20/10 (0.00%)   Vomiting 20/10 (0.00%)   Pneumonia 20/10 (0.00%)",
      "span_granularity": "full-document",
      "p_entail": 0.37835052609443665,
      "p_contr": 0.028330326080322266,
      "p_neut": 0.5933191180229187,
      "NLIScore": 0.3500202000141144
    },
    {
      "doc_id": "NCT01439282",
      "section": "Adverse Events",
      "claim_id": "bc845a3d-1f69-41a3-bf84-36a62e8127a4",
      "claim_text": "In total cohort 1 of the primary trial recorded more than 10 times the number of adverse events as cohort 2.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Adverse Events 1:   Total: 14/67 (20.90%)   Febrile neutropenia 21/67 (1.49%)   Leukopenia 21/67 (1.49%)   Neutropenia 21/67 (1.49%)   Macular hole 21/67 (1.49%)   Diarrhoea 22/67 (2.99%)   Abdominal pain 21/67 (1.49%)   Abdominal pain upper 21/67 (1.49%)   Enteritis 21/67 (1.49%)   Gastritis 21/67 (1.49%)   Nausea 21/67 (1.49%)   Vomiting 21/67 (1.49%)   Pneumonia 21/67 (1.49%) Adverse Events 2:   Total: 1/10 (10.00%)   Febrile neutropenia 20/10 (0.00%)   Leukopenia 20/10 (0.00%)   Neutropenia 20/10 (0.00%)   Macular hole 20/10 (0.00%)   Diarrhoea 20/10 (0.00%)   Abdominal pain 20/10 (0.00%)   Abdominal pain upper 20/10 (0.00%)   Enteritis 20/10 (0.00%)   Gastritis 20/10 (0.00%)   Nausea 20/10 (0.00%)   Vomiting 20/10 (0.00%)   Pneumonia 20/10 (0.00%)",
      "span_granularity": "full-document",
      "p_entail": 0.4977693259716034,
      "p_contr": 0.13186074793338776,
      "p_neut": 0.3703698515892029,
      "NLIScore": 0.36590857803821564
    },
    {
      "doc_id": "NCT01702571",
      "section": "Adverse Events",
      "claim_id": "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10",
      "claim_text": "there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%)   FEBRILE NEUTROPENIA 1/2002 (0.05%)   THROMBOCYTOPENIA 11/2002 (0.55%)   ACUTE CORONARY SYNDROME 3/2002 (0.15%)   ANGINA PECTORIS 1/2002 (0.05%)",
      "span_granularity": "paragraph",
      "p_entail": 0.622326135635376,
      "p_contr": 0.0032713657710701227,
      "p_neut": 0.3744025230407715,
      "NLIScore": 0.6190547698643059
    },
    {
      "doc_id": "NCT01702571",
      "section": "Adverse Events",
      "claim_id": "1cda1a1d-3ca1-4838-9054-bcab763bb5d0",
      "claim_text": "All of the Aes recorded for cohort 1 of the primary trial are related to mental health",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  ACUTE CORONARY SYNDROME 1/181 (0.55%)   ANGINA PECTORIS 0/181 (0.00%)   CARDIAC ARREST 0/181 (0.00%)   CARDIAC FAILURE 0/181 (0.00%)   CARDIAC TAMPONADE 0/181 (0.00%)",
      "span_granularity": "paragraph",
      "p_entail": 0.06210266426205635,
      "p_contr": 0.0208450835198164,
      "p_neut": 0.917052149772644,
      "NLIScore": 0.04125758074223995
    },
    {
      "doc_id": "NCT01702571",
      "section": "Adverse Events",
      "claim_id": "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10",
      "claim_text": "there are several different instances of cardiac related adverse events recorded for cohort 1 of the primary trial",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  DISSEMINATED INTRAVASCULAR COAGULATION 1/2002 (0.05%)   FEBRILE NEUTROPENIA 1/2002 (0.05%)   THROMBOCYTOPENIA 11/2002 (0.55%)   ACUTE CORONARY SYNDROME 3/2002 (0.15%)   ANGINA PECTORIS 1/2002 (0.05%)",
      "span_granularity": "paragraph",
      "p_entail": 0.6315080523490906,
      "p_contr": 0.0017393454909324646,
      "p_neut": 0.36675265431404114,
      "NLIScore": 0.6297687068581581
    },
    {
      "doc_id": "NCT01702571",
      "section": "Adverse Events",
      "claim_id": "1cda1a1d-3ca1-4838-9054-bcab763bb5d0",
      "claim_text": "All of the adverse events recorded for cohort 1 of the primary trial are related to mental health",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:",
      "span_granularity": "sentence",
      "p_entail": 0.0013051002752035856,
      "p_contr": 0.0027918911073356867,
      "p_neut": 0.9959030747413635,
      "NLIScore": -0.001486790832132101
    },
    {
      "doc_id": "NCT00475670",
      "section": "Adverse Events",
      "claim_id": "72bb3c6e-66b0-4380-9da2-5a5867d715fd",
      "claim_text": "compared to cohort 1 of the primary trial, there are more cases of every observed adverse event in cohort 2.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Lymphoedema * 0/3 (0.00%) Adverse Events 2:   Total: 6/41 (14.63%)   Febrile Neutropenia * 1/41 (2.44%)   Neutropenia * 1/41 (2.44%)",
      "span_granularity": "paragraph",
      "p_entail": 0.24504713714122772,
      "p_contr": 0.04704109579324722,
      "p_neut": 0.7079118490219116,
      "NLIScore": 0.1980060413479805
    },
    {
      "doc_id": "NCT00475670",
      "section": "Adverse Events",
      "claim_id": "985c4cb3-2684-4a67-a479-998602044a0d",
      "claim_text": "compared to cohort 1 of the primary trial, other than sudden death, there are more cases of every observed adverse event in cohort 2.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Adverse Events 1:   Total: 0/3 (0.00%)   Febrile Neutropenia * 0/3 (0.00%)   Neutropenia * 0/3 (0.00%)   Sudden Death * 0/3 (0.00%)   Bacterial Infection * 0/3 (0.00%)   Bronchitis * 0/3 (0.00%)   Sepsis * 0/3 (0.00%)   Lymphoedema * 0/3 (0.00%) Adverse Events 2:   Total: 6/41 (14.63%)   Febrile Neutropenia * 1/41 (2.44%)   Neutropenia * 1/41 (2.44%)   Sudden Death * 1/41 (2.44%)   Bacterial Infection * 1/41 (2.44%)   Bronchitis * 1/41 (2.44%)   Sepsis * 1/41 (2.44%)   Lymphoedema * 1/41 (2.44%)",
      "span_granularity": "full-document",
      "p_entail": 0.2531038224697113,
      "p_contr": 0.05685374140739441,
      "p_neut": 0.6900424361228943,
      "NLIScore": 0.1962500810623169
    },
    {
      "doc_id": "NCT02001974",
      "section": "Adverse Events",
      "claim_id": "a49666fd-f278-4dcf-b6bf-287ace3969aa",
      "claim_text": "No cases of Metastasis to the central nervous system were recorded in the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Hypoxia 0/3 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.07436948269605637,
      "p_contr": 0.5157380700111389,
      "p_neut": 0.4098924398422241,
      "NLIScore": -0.44136858731508255
    },
    {
      "doc_id": "NCT02001974",
      "section": "Adverse Events",
      "claim_id": "c40d8532-4e66-4eef-9644-91f20a02066d",
      "claim_text": "No cases of Oesophageal adenocarcinoma were recorded in the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Abdominal pain 0/4 (0.00%)",
      "span_granularity": "sentence",
      "p_entail": 0.00680861622095108,
      "p_contr": 0.6770226955413818,
      "p_neut": 0.3161686360836029,
      "NLIScore": -0.6702140793204308
    },
    {
      "doc_id": "NCT00089999",
      "section": "Results",
      "claim_id": "7c1b03bc-d299-4ee8-b9ee-3d253f3fc33a",
      "claim_text": "In total more participants in the primary trial had no tumor Response, than partial response, and only 3 patients had a complete response.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Overall Number of Participants Analyzed: 69   Measure Type: Number   Unit of Measure: Participants  CR: 0 PR: 15 Results 2: ",
      "span_granularity": "paragraph",
      "p_entail": 0.020840156823396683,
      "p_contr": 0.005761015694588423,
      "p_neut": 0.9733988046646118,
      "NLIScore": 0.01507914112880826
    },
    {
      "doc_id": "NCT00089999",
      "section": "Results",
      "claim_id": "108b54a9-b5cc-4f31-956f-e4e2e653d756",
      "claim_text": "In total more participants in the primary trial had no tumor Response, than partial response, and 0 participants had a complete response.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Measure Type: Number   Unit of Measure: Participants  CR: 0 PR: 15 Results 2:    Arm/Group Title: Lapatinib 500 mg BID",
      "span_granularity": "paragraph",
      "p_entail": 0.3893924355506897,
      "p_contr": 0.03996463492512703,
      "p_neut": 0.57064288854599,
      "NLIScore": 0.34942780062556267
    },
    {
      "doc_id": "NCT02658734",
      "section": "Results",
      "claim_id": "878c09e7-3fd9-404e-921e-5b549e9578fb",
      "claim_text": "Most patients in the primary trial experienced grade 1 adverse events, the least common severity was grade 4.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Outcome Measurement:    Severity of Adverse Events   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.   Time frame: From cycle 1 up to approximately 3 years Results 1:    Arm/Group Title: Trastuzumab Emtansine   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks.   Overall Number of Participants Analyzed: 70   Measure Type: Count of Participants   Unit of Measure: Participants  Grade 1: 53  75.7%   Grade 2: 40  57.1%   Grade 3: 18  25.7%   Grade 4: 2   2.9%   Grade 5: 12  17.1%",
      "span_granularity": "full-document",
      "p_entail": 0.813366174697876,
      "p_contr": 0.03452802821993828,
      "p_neut": 0.15210580825805664,
      "NLIScore": 0.7788381464779377
    },
    {
      "doc_id": "NCT02658734",
      "section": "Results",
      "claim_id": "40f699a1-fbc6-40de-8e80-85b28f71632f",
      "claim_text": "Most patients in the primary trial experienced grade 1 adverse events, the least common severity was grade 5, which only affected 8/70 patients.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Outcome Measurement:    Severity of Adverse Events   Adverse events (AEs) grading was completed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.   Time frame: From cycle 1 up to approximately 3 years Results 1:    Arm/Group Title: Trastuzumab Emtansine   Arm/Group Description: 3.6 mg/kg of trastuzumab emtansine was administered to participants intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle and was repeated every 3 weeks.   Overall Number of Participants Analyzed: 70   Measure Type: Count of Participants   Unit of Measure: Participants  Grade 1: 53  75.7%   Grade 2: 40  57.1%   Grade 3: 18  25.7%   Grade 4: 2   2.9%   Grade 5: 12  17.1%",
      "span_granularity": "full-document",
      "p_entail": 0.6484551429748535,
      "p_contr": 0.021969111636281013,
      "p_neut": 0.32957568764686584,
      "NLIScore": 0.6264860313385725
    },
    {
      "doc_id": "NCT01401166",
      "section": "Results",
      "claim_id": "16dc5a77-5758-4d19-9801-6e9932d9fbc9",
      "claim_text": "several patients in cohort 1 of the primary trial preferred oral tablets as a method of drug administration.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Time frame: Week 24",
      "span_granularity": "sentence",
      "p_entail": 0.03682258352637291,
      "p_contr": 0.013697146438062191,
      "p_neut": 0.9494801759719849,
      "NLIScore": 0.02312543708831072
    },
    {
      "doc_id": "NCT01401166",
      "section": "Results",
      "claim_id": "7926bfa3-cf49-4589-8143-0a0826336b67",
      "claim_text": "All patients in cohort 1 of the primary trial had a preferred method of drug administration.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.00225693522952497,
      "p_contr": 0.013559624552726746,
      "p_neut": 0.9841834306716919,
      "NLIScore": -0.011302689323201776
    },
    {
      "doc_id": "NCT00524303",
      "section": "Results",
      "claim_id": "f697c2d8-e0dd-476e-8ff4-dffe053076f8",
      "claim_text": "The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Arm/Group Title: Trastuzumab   Arm/Group Description: Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab.   Overall Number of Participants Analyzed: 26   Measure Type: Number   Unit of Measure: percentage of participants  54.0",
      "span_granularity": "paragraph",
      "p_entail": 0.09338274598121643,
      "p_contr": 0.02550639398396015,
      "p_neut": 0.8811108469963074,
      "NLIScore": 0.06787635199725628
    },
    {
      "doc_id": "NCT00524303",
      "section": "Results",
      "claim_id": "d23eb56e-c232-4754-94aa-903bc174cb35",
      "claim_text": "The Trastuzumab arm of the primary trial had 9% better results than the Lapatinib arm.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Time frame: Week 26",
      "span_granularity": "sentence",
      "p_entail": 0.07224853336811066,
      "p_contr": 0.06120504066348076,
      "p_neut": 0.8665464520454407,
      "NLIScore": 0.011043492704629898
    },
    {
      "doc_id": "NCT00193037",
      "section": "Results",
      "claim_id": "75affd49-4905-4d43-9a5c-ef795281bac4",
      "claim_text": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Unit of Measure: percentage of patients  28        (16 to 42)",
      "span_granularity": "sentence",
      "p_entail": 0.0022862411569803953,
      "p_contr": 0.09429201483726501,
      "p_neut": 0.9034217596054077,
      "NLIScore": -0.09200577368028462
    },
    {
      "doc_id": "NCT00193037",
      "section": "Results",
      "claim_id": "74e376d7-5713-43f3-93f1-9608059c9547",
      "claim_text": "neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients, in fact over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Time frame: 18 Months",
      "span_granularity": "sentence",
      "p_entail": 0.006647476460784674,
      "p_contr": 0.061978358775377274,
      "p_neut": 0.931374192237854,
      "NLIScore": -0.0553308823145926
    },
    {
      "doc_id": "NCT00374322",
      "section": "Results",
      "claim_id": "7eea6ac2-ef9a-4c3e-b14d-eb9671dab89d",
      "claim_text": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were twice as likely to achieve DFS at 5 years than placebo patients.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.027419861406087875,
      "p_contr": 0.0038751906249672174,
      "p_neut": 0.9687049388885498,
      "NLIScore": 0.023544670781120658
    },
    {
      "doc_id": "NCT00374322",
      "section": "Results",
      "claim_id": "0beaef44-a39a-462c-a084-d3f824857673",
      "claim_text": "the primary trial results show that Participants receiving lapatinib 1500 milligrams (mg) orally were more likely to achieve DFS at 5 years than placebo patients, however, there was less than a 30% difference in DFS rate between the two cohorts.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Results 2: ",
      "span_granularity": "sentence",
      "p_entail": 0.016273410990834236,
      "p_contr": 0.004499632865190506,
      "p_neut": 0.9792270064353943,
      "NLIScore": 0.01177377812564373
    },
    {
      "doc_id": "NCT00819182",
      "section": "Results",
      "claim_id": "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b",
      "claim_text": "the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Outcome Measurement: ",
      "span_granularity": "sentence",
      "p_entail": 0.1120697483420372,
      "p_contr": 0.11030414700508118,
      "p_neut": 0.7776261568069458,
      "NLIScore": 0.0017656013369560242
    },
    {
      "doc_id": "NCT00819182",
      "section": "Results",
      "claim_id": "dfd8e736-5ef2-4d36-b124-9382e72f982d",
      "claim_text": "the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.22335368394851685,
      "p_contr": 0.03802928328514099,
      "p_neut": 0.7386170029640198,
      "NLIScore": 0.18532440066337585
    },
    {
      "doc_id": "NCT00819182",
      "section": "Results",
      "claim_id": "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b",
      "claim_text": "the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Outcome Measurement: ",
      "span_granularity": "sentence",
      "p_entail": 0.1120697483420372,
      "p_contr": 0.11030414700508118,
      "p_neut": 0.7776261568069458,
      "NLIScore": 0.0017656013369560242
    },
    {
      "doc_id": "NCT00819182",
      "section": "Results",
      "claim_id": "dfd8e736-5ef2-4d36-b124-9382e72f982d",
      "claim_text": "the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.22335368394851685,
      "p_contr": 0.03802928328514099,
      "p_neut": 0.7386170029640198,
      "NLIScore": 0.18532440066337585
    },
    {
      "doc_id": "NCT01881230",
      "section": "Results",
      "claim_id": "b8e0458c-b834-42b5-b5fd-8791f89b0853",
      "claim_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 2 months shorter than the Carboplatin group",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.05032923072576523,
      "p_contr": 0.024433182552456856,
      "p_neut": 0.9252375364303589,
      "NLIScore": 0.025896048173308372
    },
    {
      "doc_id": "NCT01881230",
      "section": "Results",
      "claim_id": "27397dfc-b6cf-41a3-862c-a99ccd2ddd5d",
      "claim_text": "The Gemcitabine group of the primary trial had a median Kaplan-Meier Estimate of Progression-Free Survival more than 83% less than the Carboplatin group",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.04332966357469559,
      "p_contr": 0.02285103313624859,
      "p_neut": 0.9338192939758301,
      "NLIScore": 0.020478630438447
    },
    {
      "doc_id": "NCT01466270",
      "section": "Results",
      "claim_id": "f2bd0a9c-74c4-443e-b666-0a0b3aa125e1",
      "claim_text": "The primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Time frame: 24 Weeks",
      "span_granularity": "sentence",
      "p_entail": 0.10597903281450272,
      "p_contr": 0.05185222998261452,
      "p_neut": 0.8421686887741089,
      "NLIScore": 0.0541268028318882
    },
    {
      "doc_id": "NCT01466270",
      "section": "Results",
      "claim_id": "c524ecf2-1ca6-4a9a-bedf-f0709124fa1b",
      "claim_text": "The primary trial placebo group had an over 10% higher mean retention than the donepezil hydrochloride PO QD group.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Arm/Group Description: Patients receive placebo PO QD.",
      "span_granularity": "sentence",
      "p_entail": 0.0008561803260818124,
      "p_contr": 0.0015814841026440263,
      "p_neut": 0.9975622892379761,
      "NLIScore": -0.0007253037765622139
    },
    {
      "doc_id": "NCT01091168",
      "section": "Results",
      "claim_id": "f2f05760-cc22-4fe8-a24f-f6d43f9c9a86",
      "claim_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year, however several patients in the alkylating agent arm survived longer than a year.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Outcome Measurement:    Overall Survival   The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up. For patients who have not died, survival duration will be censored at the date of last contact or last follow-up or the date of last news.   Time frame: From baseline up to 3 years 1 month Results 1:    Arm/Group Title: Vinflunine   Arm/Group Description: Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m  on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.   vinflunine: 280 mg/m2 on day 1 of each cycle every 3 weeks   Overall Number of Participants Analyzed: 298   Median (95% Confidence Interval)   Unit of Measure: Months  9.1        (7.7 to 10.4) Results 2:    Arm/Group Title: Alkylating Agent   Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.   Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin   Overall Number of Participants Analyzed: 296   Median (95% Confidence Interval)   Unit of Measure: Months  9.3        (7.5 to 10.9)",
      "span_granularity": "full-document",
      "p_entail": 0.2797130346298218,
      "p_contr": 0.13788114488124847,
      "p_neut": 0.5824058055877686,
      "NLIScore": 0.1418318897485733
    },
    {
      "doc_id": "NCT01091168",
      "section": "Results",
      "claim_id": "5bc0d21d-a040-4d30-b0c7-8793cba6aba8",
      "claim_text": "Patients in the control group of the primary trial had a median Overall Survival of less than a year.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Outcome Measurement:    Overall Survival   The main endpoint of this study is overall survival defined as the time from randomisation to the date of death or last follow-up. For patients who have not died, survival duration will be censored at the date of last contact or last follow-up or the date of last news.   Time frame: From baseline up to 3 years 1 month Results 1:    Arm/Group Title: Vinflunine   Arm/Group Description: Patients randomised in the test arm (arm A) received VFL at the dose of 280 mg/m  on day 1 of each cycle every 3 weeks, over a 20-minute intravenous (IV) infusion. Cycles were repeated every 3 weeks.   vinflunine: 280 mg/m2 on day 1 of each cycle every 3 weeks   Overall Number of Participants Analyzed: 298   Median (95% Confidence Interval)   Unit of Measure: Months  9.1        (7.7 to 10.4) Results 2:    Arm/Group Title: Alkylating Agent   Arm/Group Description: Patients randomised in the control arm (arm B) received an alkylating agent used as a single agent which was available in the investigational center and was approved for the treatment of cancer in the country.   Alkylating agent of physician choice registered in cancer: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin   Overall Number of Participants Analyzed: 296   Median (95% Confidence Interval)   Unit of Measure: Months  9.3        (7.5 to 10.9)",
      "span_granularity": "full-document",
      "p_entail": 0.48950687050819397,
      "p_contr": 0.12106295675039291,
      "p_neut": 0.3894301652908325,
      "NLIScore": 0.36844391375780106
    },
    {
      "doc_id": "NCT00633464",
      "section": "Results",
      "claim_id": "93fc76a9-5f3d-490b-8802-21d0fa806728",
      "claim_text": "Cohort 2 of the primary trial reported worse results than cohort 1.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "Results 2: ",
      "span_granularity": "sentence",
      "p_entail": 0.008710779249668121,
      "p_contr": 0.04492209106683731,
      "p_neut": 0.9463671445846558,
      "NLIScore": -0.03621131181716919
    },
    {
      "doc_id": "NCT00633464",
      "section": "Results",
      "claim_id": "2514da19-b30a-44bb-8853-4545e97295da",
      "claim_text": "The Ixabepilone 40 mg/m^2 group in the primary trial reported worse results than the Cetuximab 250 mg/m^2 + Ixabepilone 40 mg/m^2 group.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Arm/Group Title: Ixabepilone 40 mg/m^2",
      "span_granularity": "sentence",
      "p_entail": 0.0037426555063575506,
      "p_contr": 0.026018518954515457,
      "p_neut": 0.9702388048171997,
      "NLIScore": -0.022275863448157907
    },
    {
      "doc_id": "NCT00820170",
      "section": "Results",
      "claim_id": "958721dc-e374-4fd1-abb9-071add70bde3",
      "claim_text": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Outcome Measurement:    Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.   [Not Specified]   Time frame: Through completion of Phase I, up to 1 year Results 1:    Arm/Group Title: Dasatinib and Paclitaxel   Arm/Group Description: The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.   The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel.   Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days, according to the following schedule:   Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.   The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.   Overall Number of Participants Analyzed: 15   Measure Type: Number   Unit of Measure: mg of dasatinib  120",
      "span_granularity": "full-document",
      "p_entail": 0.620990514755249,
      "p_contr": 0.047630421817302704,
      "p_neut": 0.3313790559768677,
      "NLIScore": 0.5733600929379463
    },
    {
      "doc_id": "NCT00820170",
      "section": "Results",
      "claim_id": "3f012bd3-bb89-414b-9dd9-35cef524a69a",
      "claim_text": "According to the results of the primary trial the MTD of dasatinib in combination with weekly paclitaxel is approximately is 120 mg.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Outcome Measurement:    Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel.   [Not Specified]   Time frame: Through completion of Phase I, up to 1 year Results 1:    Arm/Group Title: Dasatinib and Paclitaxel   Arm/Group Description: The phase I portion is a standard, three-patient per cohort, dose escalation schedule will be used. Between 6 and 54 patients will likely be necessary to determine the MTD of dasatinib in combination with weekly paclitaxel.   The phase II portion of this trial has a Simon two-stage design to determine the efficacy of dasatinib when administered in combination with paclitaxel.   Dasatinib and Paclitaxel: A treatment cycle will consist of 28 days, according to the following schedule:   Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.   The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel.   Overall Number of Participants Analyzed: 15   Measure Type: Number   Unit of Measure: mg of dasatinib  120",
      "span_granularity": "full-document",
      "p_entail": 0.620990514755249,
      "p_contr": 0.047630421817302704,
      "p_neut": 0.3313790559768677,
      "NLIScore": 0.5733600929379463
    },
    {
      "doc_id": "NCT00313170",
      "section": "Results",
      "claim_id": "6550c068-14e6-4e93-8f98-756338c91e35",
      "claim_text": "Patients in the primary trial treated with Fulvestrant 250 mg had a higher Objective response rate than those treated with Fulvestrant 250 mg + Loading Dose.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.1009388342499733,
      "p_contr": 0.032107025384902954,
      "p_neut": 0.8669542074203491,
      "NLIScore": 0.06883180886507034
    },
    {
      "doc_id": "NCT00305448",
      "section": "Results",
      "claim_id": "589e2f5b-9286-465b-8162-bb1549cd5ece",
      "claim_text": "At least 4 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR).",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Objective Response Rate (ORR)",
      "span_granularity": "sentence",
      "p_entail": 0.14393527805805206,
      "p_contr": 0.03294473886489868,
      "p_neut": 0.8231199383735657,
      "NLIScore": 0.11099053919315338
    },
    {
      "doc_id": "NCT00305448",
      "section": "Results",
      "claim_id": "6ce047b6-c18f-4f63-90ec-8643f5145efe",
      "claim_text": "At least 11 patients in both cohorts of the primary trial achieved either complete response (CR) or partial response (PR).",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Measure Type: Number   Unit of Measure: percentage of participants  11.1 Results 2:    Arm/Group Title: Fulvestrant 250 mg + Loading Dose   Arm/Group Description: Fulvestrant 250 mg + Loading Dose",
      "span_granularity": "paragraph",
      "p_entail": 0.1684270203113556,
      "p_contr": 0.012351833283901215,
      "p_neut": 0.8192211389541626,
      "NLIScore": 0.15607518702745438
    },
    {
      "doc_id": "NCT01827787",
      "section": "Results",
      "claim_id": "58c58b68-fc9a-438c-8a85-9233dde714c9",
      "claim_text": "The TNBC cohort of the primary trial had a much lower ORR than the HR+/HER2- cohort.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Arm/Group Title: Cohort 2: TNBC",
      "span_granularity": "sentence",
      "p_entail": 0.001026689657010138,
      "p_contr": 0.001960895024240017,
      "p_neut": 0.9970124959945679,
      "NLIScore": -0.0009342053672298789
    },
    {
      "doc_id": "NCT01827787",
      "section": "Results",
      "claim_id": "601e9c47-ed82-4fa6-8a28-b3c71cc7c71b",
      "claim_text": "The TNBC cohort of the primary trial had a much lower ORR than the cohort receiving 1.4 mg/m2 of Eribulin.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Arm/Group Title: Cohort 2: TNBC",
      "span_granularity": "sentence",
      "p_entail": 0.0011804928071796894,
      "p_contr": 0.0022374072577804327,
      "p_neut": 0.9965820908546448,
      "NLIScore": -0.0010569144506007433
    },
    {
      "doc_id": "NCT02679755",
      "section": "Results",
      "claim_id": "69b12ff4-6bb4-4207-b400-67795709c3c8",
      "claim_text": "Every patient in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product; the event did not need to have a causal relationship with the treatment. All AEs reported after initiation of study drug treatment were considered as treatment emergent adverse events (TEAEs). AE severity was graded according to Common Terminology Criteria for AEs (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.",
      "span_granularity": "sentence",
      "p_entail": 0.0055750091560184956,
      "p_contr": 0.031621355563402176,
      "p_neut": 0.9628036618232727,
      "NLIScore": -0.02604634640738368
    },
    {
      "doc_id": "NCT02679755",
      "section": "Results",
      "claim_id": "ce6630d3-d3b7-4870-a486-9b6284a454f0",
      "claim_text": "More patients in the Palbociclib+Letrozole Australia Cohort of the primary trial experienced Treatment-Emergent Adverse Events compared to patients in the Palbociclib+Letrozole India Cohort.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Number of Participants With Treatment-Emergent Adverse Events (All Causalities)",
      "span_granularity": "sentence",
      "p_entail": 0.009335920214653015,
      "p_contr": 0.012414882890880108,
      "p_neut": 0.978249192237854,
      "NLIScore": -0.0030789626762270927
    },
    {
      "doc_id": "NCT00436566",
      "section": "Results",
      "claim_id": "76362fd3-3a07-4aa3-a072-b9075d2ea791",
      "claim_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure (during active treatment).",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.",
      "span_granularity": "sentence",
      "p_entail": 0.010887756943702698,
      "p_contr": 0.1720128059387207,
      "p_neut": 0.8170994520187378,
      "NLIScore": -0.161125048995018
    },
    {
      "doc_id": "NCT00436566",
      "section": "Results",
      "claim_id": "8e246d8f-e063-4f2e-a382-5d201a946b87",
      "claim_text": "Not a single patient in the primary trial suffered from Congestive Heart Failure during active treatment with Trastuzumab and RAD001.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.",
      "span_granularity": "sentence",
      "p_entail": 0.012361128814518452,
      "p_contr": 0.06135883182287216,
      "p_neut": 0.9262800812721252,
      "NLIScore": -0.04899770300835371
    },
    {
      "doc_id": "NCT02513472",
      "section": "Results",
      "claim_id": "bcb2d4a9-f2da-4a51-861b-3d5a9fbb6541",
      "claim_text": "Cohort 1 patients in the primary trial survived almost twice as long as those in cohort 2.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Measure Type: Number",
      "span_granularity": "sentence",
      "p_entail": 0.050048910081386566,
      "p_contr": 0.026110369712114334,
      "p_neut": 0.9238407611846924,
      "NLIScore": 0.023938540369272232
    },
    {
      "doc_id": "NCT02513472",
      "section": "Results",
      "claim_id": "b1060434-0f7c-4c4a-bcff-53c3124bb51e",
      "claim_text": "Cohort 1 of the primary trial produced better Objective Response Rate results than cohort 2.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Measure Type: Number",
      "span_granularity": "sentence",
      "p_entail": 0.15599218010902405,
      "p_contr": 0.0478094108402729,
      "p_neut": 0.7961983680725098,
      "NLIScore": 0.10818276926875114
    },
    {
      "doc_id": "NCT01202591",
      "section": "Results",
      "claim_id": "cdba382e-894b-4f79-a8e2-ff818746adc5",
      "claim_text": "100% of patients in the primary trial suffered adverse events.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Time frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).",
      "span_granularity": "sentence",
      "p_entail": 0.0013230800395831466,
      "p_contr": 0.0395989790558815,
      "p_neut": 0.9590779542922974,
      "NLIScore": -0.038275899016298354
    },
    {
      "doc_id": "NCT01202591",
      "section": "Results",
      "claim_id": "4bd9f061-6420-443d-8f84-b703733644ac",
      "claim_text": "100% of patients in the primary trial suffered life threatening adverse events.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Time frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).",
      "span_granularity": "sentence",
      "p_entail": 0.0006958000594750047,
      "p_contr": 0.015020383521914482,
      "p_neut": 0.9842838048934937,
      "NLIScore": -0.014324583462439477
    },
    {
      "doc_id": "NCT01271725",
      "section": "Results",
      "claim_id": "db8ffa86-bf52-47bb-89f7-42e7ae47b84d",
      "claim_text": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 18% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Unit of Measure: Percentage of participants  18        (10 to 28) Results 2:    Arm/Group Title: Afatinib and Paclitaxel or Vinorelbine Combination Therapy   Arm/Group Description: Patient received Afatinib monotherapy orally once daily at a dose of 40 mg film-coated tablets until progression of their disease, unacceptable adverse events or other reason necessitating withdrawal (Patients could have dose reduced if 40 mg was not tolerated) and 80 mg/square meter (m2) Paclitaxel concentrate for intravenous infusion or 25 mg/m2 Vinorelbine concentrate for intravenous infusion once weekly starting after treatment failure on afatinib monotherapy   Overall Number of Participants Analyzed: 39",
      "span_granularity": "paragraph",
      "p_entail": 0.09522826969623566,
      "p_contr": 0.027042986825108528,
      "p_neut": 0.8777287602424622,
      "NLIScore": 0.06818528287112713
    },
    {
      "doc_id": "NCT01271725",
      "section": "Results",
      "claim_id": "9b03c9e7-ca64-4e9f-9c10-f8c2d64ff0b7",
      "claim_text": "In the primary trial The Percentage of Participants With Objective Response (OR) for the Afatinib Monotherapy was 13% lower than the Afatinib and Paclitaxel or Vinorelbine Combination Therapy group.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.06877940893173218,
      "p_contr": 0.023492101579904556,
      "p_neut": 0.9077285528182983,
      "NLIScore": 0.04528730735182762
    },
    {
      "doc_id": "NCT02273206",
      "section": "Results",
      "claim_id": "80a26581-a95c-4c22-864f-93425b1fc165",
      "claim_text": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type.",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.0014511571498587728,
      "p_contr": 0.0015516348648816347,
      "p_neut": 0.9969972372055054,
      "NLIScore": -0.00010047771502286196
    },
    {
      "doc_id": "NCT02273206",
      "section": "Results",
      "claim_id": "585b42d5-c81a-482a-a6bf-b7db6c6edcfb",
      "claim_text": "Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  Cervical Cancer Screening - Baseline: 42.3   Cervical Cancer Screening - Follow Up: 61.6 Results 2:    Arm/Group Title: Prevention Care Management (PCM)   Arm/Group Description: The PCM intervention consisted of cancer screening telephone support, including education, patient navigation, and motivational interviewing to overcome barriers to screening",
      "span_granularity": "paragraph",
      "p_entail": 0.15466739237308502,
      "p_contr": 0.14074179530143738,
      "p_neut": 0.7045907974243164,
      "NLIScore": 0.013925597071647644
    },
    {
      "doc_id": "NCT02273206",
      "section": "Results",
      "claim_id": "80a26581-a95c-4c22-864f-93425b1fc165",
      "claim_text": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "Results 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.0014511571498587728,
      "p_contr": 0.0015516348648816347,
      "p_neut": 0.9969972372055054,
      "NLIScore": -0.00010047771502286196
    },
    {
      "doc_id": "NCT02273206",
      "section": "Results",
      "claim_id": "585b42d5-c81a-482a-a6bf-b7db6c6edcfb",
      "claim_text": "Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Cervical Cancer Screening - Baseline: 42.3   Cervical Cancer Screening - Follow Up: 61.6 Results 2:    Arm/Group Title: Prevention Care Management (PCM)   Arm/Group Description: The PCM intervention consisted of cancer screening telephone support, including education, patient navigation, and motivational interviewing to overcome barriers to screening",
      "span_granularity": "paragraph",
      "p_entail": 0.15466739237308502,
      "p_contr": 0.14074179530143738,
      "p_neut": 0.7045907974243164,
      "NLIScore": 0.013925597071647644
    },
    {
      "doc_id": "NCT00372424",
      "section": "Results",
      "claim_id": "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9",
      "claim_text": "All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Outcome Measurement:    Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)   An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.   Time frame: From screening until 28 days post last dose of study drug Results 1:    Arm/Group Title: Sunitinib + Docetaxel + Trastuzumab   Arm/Group Description: Sunitinib 37.5 milligram (mg) capsule orally once daily continuously starting from Day 2 up to Day 15 in each cycle, in schedule 2/1 (2 week on treatment, 1 week off treatment) along with docetaxel 75 milligram/square meter (mg/m^2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly: loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes; or every 3 weeks: loading dose of 8 mg/kg intravenous infusion over 90 minutes on Day 1 followed by maintenance doses of 6 mg/kg intravenous infusion over 90 minutes every 3 weeks. Cycle length was 3 weeks.   Overall Number of Participants Analyzed: 25   Measure Type: Number   Unit of Measure: participants  AEs: 24 SAEs: 11",
      "span_granularity": "full-document",
      "p_entail": 0.31987375020980835,
      "p_contr": 0.20524434745311737,
      "p_neut": 0.47488194704055786,
      "NLIScore": 0.11462940275669098
    },
    {
      "doc_id": "NCT00372424",
      "section": "Results",
      "claim_id": "04178e95-d808-4a96-ab85-61eb52c17720",
      "claim_text": "a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "Outcome Measurement:    Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)   An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.   Time frame: From screening until 28 days post last dose of study drug Results 1:    Arm/Group Title: Sunitinib + Docetaxel + Trastuzumab   Arm/Group Description: Sunitinib 37.5 milligram (mg) capsule orally once daily continuously starting from Day 2 up to Day 15 in each cycle, in schedule 2/1 (2 week on treatment, 1 week off treatment) along with docetaxel 75 milligram/square meter (mg/m^2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly: loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes; or every 3 weeks: loading dose of 8 mg/kg intravenous infusion over 90 minutes on Day 1 followed by maintenance doses of 6 mg/kg intravenous infusion over 90 minutes every 3 weeks. Cycle length was 3 weeks.   Overall Number of Participants Analyzed: 25   Measure Type: Number   Unit of Measure: participants  AEs: 24 SAEs: 11",
      "span_granularity": "full-document",
      "p_entail": 0.35421326756477356,
      "p_contr": 0.15844854712486267,
      "p_neut": 0.48733821511268616,
      "NLIScore": 0.1957647204399109
    },
    {
      "doc_id": "NCT00372424",
      "section": "Results",
      "claim_id": "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9",
      "claim_text": "All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "Outcome Measurement:    Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)   An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.   Time frame: From screening until 28 days post last dose of study drug Results 1:    Arm/Group Title: Sunitinib + Docetaxel + Trastuzumab   Arm/Group Description: Sunitinib 37.5 milligram (mg) capsule orally once daily continuously starting from Day 2 up to Day 15 in each cycle, in schedule 2/1 (2 week on treatment, 1 week off treatment) along with docetaxel 75 milligram/square meter (mg/m^2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly: loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes; or every 3 weeks: loading dose of 8 mg/kg intravenous infusion over 90 minutes on Day 1 followed by maintenance doses of 6 mg/kg intravenous infusion over 90 minutes every 3 weeks. Cycle length was 3 weeks.   Overall Number of Participants Analyzed: 25   Measure Type: Number   Unit of Measure: participants  AEs: 24 SAEs: 11",
      "span_granularity": "full-document",
      "p_entail": 0.31987375020980835,
      "p_contr": 0.20524434745311737,
      "p_neut": 0.47488194704055786,
      "NLIScore": 0.11462940275669098
    },
    {
      "doc_id": "NCT00372424",
      "section": "Results",
      "claim_id": "04178e95-d808-4a96-ab85-61eb52c17720",
      "claim_text": "A total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Outcome Measurement:    Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)   An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.   Time frame: From screening until 28 days post last dose of study drug Results 1:    Arm/Group Title: Sunitinib + Docetaxel + Trastuzumab   Arm/Group Description: Sunitinib 37.5 milligram (mg) capsule orally once daily continuously starting from Day 2 up to Day 15 in each cycle, in schedule 2/1 (2 week on treatment, 1 week off treatment) along with docetaxel 75 milligram/square meter (mg/m^2) intravenous infusion over 1 hour on Day 1 of each cycle and trastuzumab either weekly: loading dose of 4 milligram/kilogram (mg/kg) intravenous infusion over 90 minutes on Day 1 followed by weekly maintenance doses of 2 mg/kg intravenous infusion over 30 minutes; or every 3 weeks: loading dose of 8 mg/kg intravenous infusion over 90 minutes on Day 1 followed by maintenance doses of 6 mg/kg intravenous infusion over 90 minutes every 3 weeks. Cycle length was 3 weeks.   Overall Number of Participants Analyzed: 25   Measure Type: Number   Unit of Measure: participants  AEs: 24 SAEs: 11",
      "span_granularity": "full-document",
      "p_entail": 0.35472482442855835,
      "p_contr": 0.1572486311197281,
      "p_neut": 0.48802652955055237,
      "NLIScore": 0.19747619330883026
    },
    {
      "doc_id": "NCT00119262",
      "section": "Results",
      "claim_id": "d3ca3729-2795-4cd5-9968-666781d17fac",
      "claim_text": "cohorts 1 and 2 of the primary trial recorded a different number of patients that suffered from Congestive Heart Failure.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "Outcome Measurement:    Congestive Heart Failure Rate   Clinical congestive heart failure includes patients with symptomatic decline in LVEF to at or below the lower limit of normal (LLN), or symptomatic diastolic dysfunction. 223 treated patients were included in the analysis.   Time frame: assessed on day 1 of cycles 5, 9, 17 and 25, and at end of treatment, then every 3 months for <2 years and every 6 months for 2-3 years from study entry Results 1:    Arm/Group Title: Arm A (ddBAC > BT > B)   Arm/Group Description: Dose dense bevacizumab, cyclophosphamide and doxorubicin, followed by paclitaxel and bevacizumab, followed by bevacizumab   Overall Number of Participants Analyzed: 103   Measure Type: Number   Unit of Measure: percentage of participants  2.9        (0.6 to 8.3) Results 2:    Arm/Group Title: Arm B (ddAC > BT > B)   Arm/Group Description: Dose dense doxorubicin and cyclophosphamide, followed by paclitaxel and bevacizumab, followed by bevacizumab   Overall Number of Participants Analyzed: 120   Measure Type: Number   Unit of Measure: percentage of participants  2.5        (0.5 to 7.1)",
      "span_granularity": "full-document",
      "p_entail": 0.5053611993789673,
      "p_contr": 0.026158513501286507,
      "p_neut": 0.46848034858703613,
      "NLIScore": 0.4792026858776808
    },
    {
      "doc_id": "NCT00119262",
      "section": "Results",
      "claim_id": "1a32e1c1-31b1-40e5-bbb6-84041ef796fe",
      "claim_text": "cohorts 1 and 2 of the primary trial both had 3 patients that suffered from Congestive Heart Failure.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Measure Type: Number",
      "span_granularity": "sentence",
      "p_entail": 0.10503017157316208,
      "p_contr": 0.06106611713767052,
      "p_neut": 0.8339037299156189,
      "NLIScore": 0.04396405443549156
    },
    {
      "doc_id": "NCT00319254",
      "section": "Results",
      "claim_id": "94fc10ff-65e1-4b0a-8ff3-1cc48db3433e",
      "claim_text": "the primary trial did not use overall response rate, tumour response rate or progression-free survival rate as its outcome measurement.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Unit of Measure: percentage of participants  39.6        (28.1 to 50.8)",
      "span_granularity": "sentence",
      "p_entail": 0.05012138932943344,
      "p_contr": 0.08496134728193283,
      "p_neut": 0.8649172782897949,
      "NLIScore": -0.03483995795249939
    },
    {
      "doc_id": "NCT00319254",
      "section": "Results",
      "claim_id": "5c676007-9ea4-4f80-82dd-89293237cb07",
      "claim_text": "the primary trial did not use overall response rate, tumour response rate or preference score as its outcome measurement.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Measure Type: Number",
      "span_granularity": "sentence",
      "p_entail": 0.05183488130569458,
      "p_contr": 0.06502348929643631,
      "p_neut": 0.8831416368484497,
      "NLIScore": -0.01318860799074173
    },
    {
      "doc_id": "NCT01519700",
      "section": "Results",
      "claim_id": "dfa2ecee-96cf-4551-875e-aedd8aac5df9",
      "claim_text": "There was less than 24hrs difference in Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Arm/Group Title: EP2006 + EP2006 & Neupogen   Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1   Overall Number of Participants Analyzed: 101   Mean (Standard Deviation)   Unit of Measure: Days  1.17         (1.11)",
      "span_granularity": "paragraph",
      "p_entail": 0.46166014671325684,
      "p_contr": 0.011162136681377888,
      "p_neut": 0.5271778106689453,
      "NLIScore": 0.45049801003187895
    },
    {
      "doc_id": "NCT01519700",
      "section": "Results",
      "claim_id": "edf813c0-2271-49ca-a040-a355bf71d8b4",
      "claim_text": "There was just over 36 hours difference in Median Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy for the two arms of the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Arm/Group Title: EP2006 + EP2006 & Neupogen   Arm/Group Description: All subjects randomized to receive either EP2006 in Cycle 1   Overall Number of Participants Analyzed: 101   Mean (Standard Deviation)   Unit of Measure: Days  1.17         (1.11)",
      "span_granularity": "paragraph",
      "p_entail": 0.27716535329818726,
      "p_contr": 0.02930736169219017,
      "p_neut": 0.6935272812843323,
      "NLIScore": 0.24785799160599709
    },
    {
      "doc_id": "NCT01597193",
      "section": "Intervention",
      "claim_id": "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546",
      "claim_text": "cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1:    Dose Escalation: Enzalutamide 80 mg   Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. INTERVENTION 2:    Dose Escalation: Enzalutamide 160 mg   Participants received enzalutamide 160 mg (four 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.",
      "span_granularity": "full-document",
      "p_entail": 0.2757091522216797,
      "p_contr": 0.03847084566950798,
      "p_neut": 0.6858199834823608,
      "NLIScore": 0.2372383065521717
    },
    {
      "doc_id": "NCT01597193",
      "section": "Intervention",
      "claim_id": "42c38d71-6a83-4967-ad81-ec38c6b5aafd",
      "claim_text": "cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1:    Dose Escalation: Enzalutamide 80 mg   Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. INTERVENTION 2:    Dose Escalation: Enzalutamide 160 mg",
      "span_granularity": "paragraph",
      "p_entail": 0.04894780367612839,
      "p_contr": 0.019374746829271317,
      "p_neut": 0.9316774010658264,
      "NLIScore": 0.02957305684685707
    },
    {
      "doc_id": "NCT01597193",
      "section": "Intervention",
      "claim_id": "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546",
      "claim_text": "cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 receives it by IV",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1:    Dose Escalation: Enzalutamide 80 mg   Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. INTERVENTION 2:    Dose Escalation: Enzalutamide 160 mg   Participants received enzalutamide 160 mg (four 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first.",
      "span_granularity": "full-document",
      "p_entail": 0.2538936138153076,
      "p_contr": 0.03726142272353172,
      "p_neut": 0.7088449597358704,
      "NLIScore": 0.2166321910917759
    },
    {
      "doc_id": "NCT01597193",
      "section": "Intervention",
      "claim_id": "42c38d71-6a83-4967-ad81-ec38c6b5aafd",
      "claim_text": "cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    Dose Escalation: Enzalutamide 80 mg   Participants received enzalutamide 80 mg (two 40 mg) capsules, orally, once daily until documented disease progression, initiation of a new antitumor treatment, an intolerable adverse event (including any seizure), noncompliance, withdrawal of consent, discontinuation by sponsor, or investigator. Participants were followed-up until 30 days after last dose of study drug or before initiation of a new antitumor or investigational therapy, whichever occurred first. INTERVENTION 2:    Dose Escalation: Enzalutamide 160 mg",
      "span_granularity": "paragraph",
      "p_entail": 0.04894780367612839,
      "p_contr": 0.019374746829271317,
      "p_neut": 0.9316774010658264,
      "NLIScore": 0.02957305684685707
    },
    {
      "doc_id": "NCT00290745",
      "section": "Intervention",
      "claim_id": "24eced44-40b2-4365-abd3-42eb13220cf0",
      "claim_text": "There is no radiotherapy or educational part of the intervention used in the primary trial.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Tamoxifen or Letrozole   tamoxifen or letrozole work in treating women with ductal carcinoma in situ   letrozole   tamoxifen citrate   conventional surgery",
      "span_granularity": "paragraph",
      "p_entail": 0.002085847547277808,
      "p_contr": 0.02458707056939602,
      "p_neut": 0.973327100276947,
      "NLIScore": -0.02250122302211821
    },
    {
      "doc_id": "NCT00290745",
      "section": "Intervention",
      "claim_id": "3ab9c66c-06fc-4bc5-b504-d9193efa8701",
      "claim_text": "In the primary trial participants from different ethnicities receive different interventions.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  tamoxifen citrate",
      "span_granularity": "sentence",
      "p_entail": 0.06975580006837845,
      "p_contr": 0.05238531902432442,
      "p_neut": 0.8778589963912964,
      "NLIScore": 0.01737048104405403
    },
    {
      "doc_id": "NCT00354640",
      "section": "Intervention",
      "claim_id": "45fb84a3-674c-40f5-ac8c-26a3c7844e7b",
      "claim_text": "Patients taking Intervention 1 of the primary trial receive 4 times as much simvastatin as anastrozole.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  simvastatin : 40 milligram tablet PO QD for 14 days",
      "span_granularity": "sentence",
      "p_entail": 0.0007290669018402696,
      "p_contr": 0.0026741239707916975,
      "p_neut": 0.9965967535972595,
      "NLIScore": -0.001945057068951428
    },
    {
      "doc_id": "NCT00354640",
      "section": "Intervention",
      "claim_id": "bb4f69b0-0e2e-44e6-a3b6-049f4a8505fe",
      "claim_text": "Patients taking Intervention 1 of the primary trial receive higher doses of anastrozole than of simvastatin.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.005913814064115286,
      "p_contr": 0.0060195475816726685,
      "p_neut": 0.9880666732788086,
      "NLIScore": -0.00010573351755738258
    },
    {
      "doc_id": "NCT00496860",
      "section": "Intervention",
      "claim_id": "851e1a1b-0b8e-4aef-a7e3-f06c036fe537",
      "claim_text": "cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  ALT-801 0.015 mg/kg/Dose   0.015 mg/kg/dose of ALT-801 INTERVENTION 2:    ALT-801 0.040 mg/kg/Dose   0.040 mg/kg/dose of ALT-801",
      "span_granularity": "paragraph",
      "p_entail": 0.14971087872982025,
      "p_contr": 0.08643540740013123,
      "p_neut": 0.7638537287712097,
      "NLIScore": 0.06327547132968903
    },
    {
      "doc_id": "NCT00496860",
      "section": "Intervention",
      "claim_id": "b9b69888-f771-4a3a-b6f0-825510997cca",
      "claim_text": "cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1:    ALT-801 0.015 mg/kg/Dose   0.015 mg/kg/dose of ALT-801 INTERVENTION 2:    ALT-801 0.040 mg/kg/Dose",
      "span_granularity": "paragraph",
      "p_entail": 0.15893281996250153,
      "p_contr": 0.025266224518418312,
      "p_neut": 0.8158009648323059,
      "NLIScore": 0.1336665954440832
    },
    {
      "doc_id": "NCT00496860",
      "section": "Intervention",
      "claim_id": "851e1a1b-0b8e-4aef-a7e3-f06c036fe537",
      "claim_text": "cohort 1 of the primary trial is administered 0.015 mg of ALT-801 less than cohort 2",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1:    ALT-801 0.015 mg/kg/Dose   0.015 mg/kg/dose of ALT-801 INTERVENTION 2:    ALT-801 0.040 mg/kg/Dose",
      "span_granularity": "paragraph",
      "p_entail": 0.2271599918603897,
      "p_contr": 0.04331071674823761,
      "p_neut": 0.7295293211936951,
      "NLIScore": 0.1838492751121521
    },
    {
      "doc_id": "NCT00496860",
      "section": "Intervention",
      "claim_id": "b9b69888-f771-4a3a-b6f0-825510997cca",
      "claim_text": "cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    ALT-801 0.015 mg/kg/Dose   0.015 mg/kg/dose of ALT-801 INTERVENTION 2:    ALT-801 0.040 mg/kg/Dose",
      "span_granularity": "paragraph",
      "p_entail": 0.15893281996250153,
      "p_contr": 0.025266224518418312,
      "p_neut": 0.8158009648323059,
      "NLIScore": 0.1336665954440832
    },
    {
      "doc_id": "NCT01969448",
      "section": "Intervention",
      "claim_id": "6d37ed53-a6e4-403e-8b93-9954a6486dbc",
      "claim_text": "laser-assisted fluorescence angiography is used for both interventions in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1:    Inframammary Fold Incision Cohort   Inframammary fold incision which is in the crease under the breast.   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in) INTERVENTION 2:    Lateral Radial Incision Cohort   Lateral radial incision   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)",
      "span_granularity": "full-document",
      "p_entail": 0.3150961101055145,
      "p_contr": 0.015619787387549877,
      "p_neut": 0.6692841053009033,
      "NLIScore": 0.29947632271796465
    },
    {
      "doc_id": "NCT01969448",
      "section": "Intervention",
      "claim_id": "6e4be816-3da7-4def-ab23-2a4fda805cd0",
      "claim_text": "laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1:    Inframammary Fold Incision Cohort   Inframammary fold incision which is in the crease under the breast.   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in) INTERVENTION 2:    Lateral Radial Incision Cohort   Lateral radial incision   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)",
      "span_granularity": "full-document",
      "p_entail": 0.5514445304870605,
      "p_contr": 0.010399721562862396,
      "p_neut": 0.43815574049949646,
      "NLIScore": 0.5410448089241982
    },
    {
      "doc_id": "NCT01969448",
      "section": "Intervention",
      "claim_id": "6d37ed53-a6e4-403e-8b93-9954a6486dbc",
      "claim_text": "laser-assisted fluorescence angiography is used for both interventions in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    Inframammary Fold Incision Cohort   Inframammary fold incision which is in the crease under the breast.   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in) INTERVENTION 2:    Lateral Radial Incision Cohort   Lateral radial incision   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)",
      "span_granularity": "full-document",
      "p_entail": 0.3150961101055145,
      "p_contr": 0.015619787387549877,
      "p_neut": 0.6692841053009033,
      "NLIScore": 0.29947632271796465
    },
    {
      "doc_id": "NCT01969448",
      "section": "Intervention",
      "claim_id": "6e4be816-3da7-4def-ab23-2a4fda805cd0",
      "claim_text": "laser-assisted fluorescence angiography and lateral radial incisions are used for both interventions in the primary trial.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1:    Inframammary Fold Incision Cohort   Inframammary fold incision which is in the crease under the breast.   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in) INTERVENTION 2:    Lateral Radial Incision Cohort   Lateral radial incision   Perfusion of the involved breast will be monitored at three separate time points using laser-assisted fluorescence angiography (Spy Elite, LifeCell)   Intraoperatively prior to mastectomy   At the conclusion of NASSM (following completion of mastectomy procedure and prior to implant insertion during reconstruction) - (ie. Mastectomy done, implant not in yet)   Following the conclusion of reconstruction with an immediate implant and skin closure with either temporary staples or final suture placement (ie. Mastectomy done and implant in)",
      "span_granularity": "full-document",
      "p_entail": 0.5757551789283752,
      "p_contr": 0.009814555756747723,
      "p_neut": 0.4144302308559418,
      "NLIScore": 0.5659406231716275
    },
    {
      "doc_id": "NCT00871858",
      "section": "Intervention",
      "claim_id": "e78805f7-1b81-4cd9-a3c7-591886fd5d70",
      "claim_text": "Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.0054106330499053,
      "p_contr": 0.015361189842224121,
      "p_neut": 0.9792282581329346,
      "NLIScore": -0.009950556792318821
    },
    {
      "doc_id": "NCT00871858",
      "section": "Intervention",
      "claim_id": "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f",
      "claim_text": "Paclitaxel is not used in either of the primary trial interventions",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  Arm A (ANA)   Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.   anastrozole: Given orally INTERVENTION 2:    Arm B (FULV)",
      "span_granularity": "paragraph",
      "p_entail": 0.018328996375203133,
      "p_contr": 0.46290481090545654,
      "p_neut": 0.5187661647796631,
      "NLIScore": -0.4445758145302534
    },
    {
      "doc_id": "NCT00871858",
      "section": "Intervention",
      "claim_id": "e78805f7-1b81-4cd9-a3c7-591886fd5d70",
      "claim_text": "Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.0054106330499053,
      "p_contr": 0.015361189842224121,
      "p_neut": 0.9792282581329346,
      "NLIScore": -0.009950556792318821
    },
    {
      "doc_id": "NCT00871858",
      "section": "Intervention",
      "claim_id": "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f",
      "claim_text": "Paclitaxel is not used in either of the primary trial interventions",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Arm A (ANA)   Patients receive oral anastrozole as 1 mg film-coated tablets, once daily for 6 months.   anastrozole: Given orally INTERVENTION 2:    Arm B (FULV)",
      "span_granularity": "paragraph",
      "p_entail": 0.018328996375203133,
      "p_contr": 0.46290481090545654,
      "p_neut": 0.5187661647796631,
      "NLIScore": -0.4445758145302534
    },
    {
      "doc_id": "NCT02667626",
      "section": "Intervention",
      "claim_id": "741c95c7-825c-4321-8d12-9037bb701ab8",
      "claim_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing the effects of using Adjuvant Letrozole on Post-menopausal Women.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    SCPR Intervention   Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.   Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence INTERVENTION 2:    Control   Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.   Control: Web-based resource lists and text-based study adherence reminders",
      "span_granularity": "full-document",
      "p_entail": 0.29473403096199036,
      "p_contr": 0.05718358978629112,
      "p_neut": 0.6480823755264282,
      "NLIScore": 0.23755044117569923
    },
    {
      "doc_id": "NCT02667626",
      "section": "Intervention",
      "claim_id": "795d634a-9f9c-49a2-a4e7-ec99bd3600f2",
      "claim_text": "the primary trial is testing a web-based educational tool and the secondary trial is testing a medical device on Post-menopausal Women.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1:    SCPR Intervention   Young breast cancer participants will receive their SCPR and access to additional web-based educational reproductive health information, including resource lists of helpful websites, followed by regular reproductive health prompts and study adherence reminders for 24 weeks.   Reproductive Health Survivorship Care Plan (SCPR): The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence INTERVENTION 2:    Control   Young breast cancer participants randomized to the waitlist control arm will receive access to the web-based resources and study adherence reminders. At completion of the 24 weeks of follow up, they will have access to their SCPR.   Control: Web-based resource lists and text-based study adherence reminders",
      "span_granularity": "full-document",
      "p_entail": 0.2834835648536682,
      "p_contr": 0.07343722879886627,
      "p_neut": 0.6430791616439819,
      "NLIScore": 0.21004633605480194
    },
    {
      "doc_id": "NCT00586326",
      "section": "Intervention",
      "claim_id": "ea1d804d-bac9-4ebd-a6bd-0705c988927f",
      "claim_text": "The the primary trial intervention section does not outline a treatment cycle or any description of the treatment",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.01986280456185341,
      "p_contr": 0.14542198181152344,
      "p_neut": 0.8347151875495911,
      "NLIScore": -0.12555917724967003
    },
    {
      "doc_id": "NCT00586326",
      "section": "Intervention",
      "claim_id": "4f1bafd9-361f-4981-b6fd-46af736141b4",
      "claim_text": "The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses.",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.013057192787528038,
      "p_contr": 0.13053716719150543,
      "p_neut": 0.8564056158065796,
      "NLIScore": -0.1174799744039774
    },
    {
      "doc_id": "NCT00586326",
      "section": "Intervention",
      "claim_id": "ea1d804d-bac9-4ebd-a6bd-0705c988927f",
      "claim_text": "The primary trial intervention section does not outline a treatment cycle or any description of the treatment",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.021690579131245613,
      "p_contr": 0.13967908918857574,
      "p_neut": 0.8386303186416626,
      "NLIScore": -0.11798851005733013
    },
    {
      "doc_id": "NCT00586326",
      "section": "Intervention",
      "claim_id": "4f1bafd9-361f-4981-b6fd-46af736141b4",
      "claim_text": "The primary trial intervention section does not outline a treatment cycle or a description of irradiation doses.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.011673703789710999,
      "p_contr": 0.11613864451646805,
      "p_neut": 0.8721876740455627,
      "NLIScore": -0.10446494072675705
    },
    {
      "doc_id": "NCT01390064",
      "section": "Intervention",
      "claim_id": "b3c1f5d1-6f7f-4bab-a4e8-5d1dab597cc7",
      "claim_text": "The both Cohorts of the primary trial receive their treatment via Subcutaneous administration.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    Initial Cohort   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration 5 doses of 300 micrograms   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule INTERVENTION 2:    Escalation Cohort   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG Subcutaneous administration of 5 doses of 500 micrograms   Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule",
      "span_granularity": "full-document",
      "p_entail": 0.8492131233215332,
      "p_contr": 0.013348216190934181,
      "p_neut": 0.1374386101961136,
      "NLIScore": 0.835864907130599
    },
    {
      "doc_id": "NCT03374995",
      "section": "Intervention",
      "claim_id": "c207ff16-b7d0-49e4-9177-0597044f3008",
      "claim_text": "Some the primary trial subjects receiving keratin are administered topical keratin topically twice daily for approximately 3-6 weeks, others participants may have topical keratin administered by subcutaneous injection.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.05027507245540619,
      "p_contr": 0.00437278812751174,
      "p_neut": 0.9453521966934204,
      "NLIScore": 0.04590228432789445
    },
    {
      "doc_id": "NCT03374995",
      "section": "Intervention",
      "claim_id": "699d0cb5-1ebb-441d-aa7e-041a48923b00",
      "claim_text": "The primary trial subjects receiving keratin are administered topical keratin topically twice daily for approximately 3-6 weeks.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    Group I (Topical Keratin)   Patients receive topical keratin topically at least BID until the end of radiation therapy (approximately 3-6 weeks).   Quality-of-Life Assessment: Ancillary studies   Topical Keratin: Given topically",
      "span_granularity": "paragraph",
      "p_entail": 0.06618960946798325,
      "p_contr": 0.003335336921736598,
      "p_neut": 0.930475115776062,
      "NLIScore": 0.06285427254624665
    },
    {
      "doc_id": "NCT00291694",
      "section": "Intervention",
      "claim_id": "0a9a7f5b-eb32-4a11-86e3-5a9a6377eea3",
      "claim_text": "the route of administration for both celecoxib and placebo in the primary trial is a topical skin cream.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Celecoxib",
      "span_granularity": "sentence",
      "p_entail": 0.0008503490244038403,
      "p_contr": 0.002090177498757839,
      "p_neut": 0.9970595240592957,
      "NLIScore": -0.001239828474353999
    },
    {
      "doc_id": "NCT00291694",
      "section": "Intervention",
      "claim_id": "be1c82e6-200d-4bef-b723-c78655fa40e5",
      "claim_text": "the primary trial does not specify the route of administration of its interventions.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Placebo",
      "span_granularity": "sentence",
      "p_entail": 0.0851733535528183,
      "p_contr": 0.3335190713405609,
      "p_neut": 0.5813076496124268,
      "NLIScore": -0.24834571778774261
    },
    {
      "doc_id": "NCT02780713",
      "section": "Intervention",
      "claim_id": "baea8eb9-a6e7-4473-9b4b-28a4fdb531ad",
      "claim_text": "Both cohorts of the primary trial are administered the same drugs in different doses.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1:    Treatment Period 1   Participants received AZD9496 - Variant A (100 mg). INTERVENTION 2:    Treatment Period 2   Participants received AZD9496 - Reference (100 mg).",
      "span_granularity": "full-document",
      "p_entail": 0.3982125520706177,
      "p_contr": 0.1358882188796997,
      "p_neut": 0.4658992886543274,
      "NLIScore": 0.26232433319091797
    },
    {
      "doc_id": "NCT02780713",
      "section": "Intervention",
      "claim_id": "c49428a7-cc55-474e-a773-88ff2019de1b",
      "claim_text": "Both cohorts of the primary trial are administered the same doses of their respective drugs.",
      "pred_label": "contradiction",
      "gold_label": "entailment",
      "matched_span": "  Treatment Period 1",
      "span_granularity": "sentence",
      "p_entail": 0.0012396133970469236,
      "p_contr": 0.010201174765825272,
      "p_neut": 0.9885591864585876,
      "NLIScore": -0.008961561368778348
    },
    {
      "doc_id": "NCT00300781",
      "section": "Intervention",
      "claim_id": "2485a3e1-7520-47d2-b941-32ebf91e5b65",
      "claim_text": "Participants of the primary trial are assigned an intervention depending on their prior treatments.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    Neratinib 240, Prior Trastuzumab   Neratinib: 80mg capsules and 40mg coated tablets taken orally in prescribed dose of 240mg daily, as long as tolerated and disease does not worsen in participants with prior trastuzumab treatment. INTERVENTION 2:    Neratinib 240, No Prior Trastuzumab",
      "span_granularity": "paragraph",
      "p_entail": 0.341035932302475,
      "p_contr": 0.0028563677333295345,
      "p_neut": 0.6561077237129211,
      "NLIScore": 0.33817956456914544
    },
    {
      "doc_id": "NCT00300781",
      "section": "Intervention",
      "claim_id": "c8cfd67e-5fac-4bff-9296-6e42dcb09f80",
      "claim_text": "Participants of the primary trial are assigned an intervention depending on their hormone receptor status.",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  Neratinib 240, Prior Trastuzumab",
      "span_granularity": "sentence",
      "p_entail": 0.03000795654952526,
      "p_contr": 0.032843392342329025,
      "p_neut": 0.9371486902236938,
      "NLIScore": -0.0028354357928037643
    },
    {
      "doc_id": "NCT00082810",
      "section": "Intervention",
      "claim_id": "19f5ff0d-3419-4f27-a7e5-6c7291c3cd21",
      "claim_text": "Throughout the duration of the primary trial, participants receive increasing doses of Fulvestrant.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity",
      "span_granularity": "sentence",
      "p_entail": 0.7644146084785461,
      "p_contr": 0.01066269725561142,
      "p_neut": 0.22492274641990662,
      "NLIScore": 0.7537519112229347
    },
    {
      "doc_id": "NCT00082810",
      "section": "Intervention",
      "claim_id": "4ee4061e-a532-459e-8d03-3055bd92419c",
      "claim_text": "Throughout the duration of the primary trial, participants receive tipifarnib more often than Fulvestrant.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Patients receive fulvestrant 250 mg intramuscularly on day 1 and oral tipifarnib 300 mg twice daily on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity",
      "span_granularity": "sentence",
      "p_entail": 0.8287691473960876,
      "p_contr": 0.02204078994691372,
      "p_neut": 0.14919008314609528,
      "NLIScore": 0.8067283574491739
    },
    {
      "doc_id": "NCT00038467",
      "section": "Intervention",
      "claim_id": "7e283897-4d9e-4353-8331-00f8db16cc7e",
      "claim_text": "The patient groups in the primary trial each receive different oral medication, either Tamoxifen or Exemestane.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period.",
      "span_granularity": "sentence",
      "p_entail": 0.7635709643363953,
      "p_contr": 0.004593292251229286,
      "p_neut": 0.23183578252792358,
      "NLIScore": 0.758977672085166
    },
    {
      "doc_id": "NCT00038467",
      "section": "Intervention",
      "claim_id": "caa55802-329d-4a1f-a9a7-b99afc44fd67",
      "claim_text": "The patient groups in the primary trial each receive the same doses of different oral medication, either Tamoxifen or Exemestane.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1:    Exemestane   Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 milligram (mg) or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received exemestane (Aromasin) 25 mg tablet-in-capsule orally once daily for the remainder of 5-year period. INTERVENTION 2:    Tamoxifen   Participants diagnosed with breast cancer who remained disease-free after previously receiving 2 to 3 years of tamoxifen 20 mg or 30 mg tablet-in-capsule orally once daily as per standard medical practice, received the same dose of tamoxifen tablet-in-capsule orally once daily for the remainder of 5-year period.",
      "span_granularity": "full-document",
      "p_entail": 0.37694892287254333,
      "p_contr": 0.3128125071525574,
      "p_neut": 0.3102385699748993,
      "NLIScore": 0.06413641571998596
    },
    {
      "doc_id": "NCT01314963",
      "section": "Intervention",
      "claim_id": "e2979c27-0eb6-487d-a940-646685e1934b",
      "claim_text": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  The prototype intraoperative handheld gamma camera (pIHGC)   radioactive Tc99M: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. INTERVENTION 2:    Gamma Probes (GP)   Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)",
      "span_granularity": "paragraph",
      "p_entail": 0.13487036526203156,
      "p_contr": 0.014880198054015636,
      "p_neut": 0.8502494096755981,
      "NLIScore": 0.11999016720801592
    },
    {
      "doc_id": "NCT01314963",
      "section": "Intervention",
      "claim_id": "1943100e-196d-4022-a38a-9ae0dd816294",
      "claim_text": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  radioactive Tc99M: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. INTERVENTION 2:    Gamma Probes (GP)   Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)   radioactive Tc99M: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.",
      "span_granularity": "paragraph",
      "p_entail": 0.049709051847457886,
      "p_contr": 0.01062310766428709,
      "p_neut": 0.939667820930481,
      "NLIScore": 0.039085944183170795
    },
    {
      "doc_id": "NCT01314963",
      "section": "Intervention",
      "claim_id": "e2979c27-0eb6-487d-a940-646685e1934b",
      "claim_text": "The difference between intervention one and two of the primary trial is that intervention 1 uses pIHGC, and intervention 2 uses standard GP.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  The prototype intraoperative handheld gamma camera (pIHGC)   radioactive Tc99M: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. INTERVENTION 2:    Gamma Probes (GP)   Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)",
      "span_granularity": "paragraph",
      "p_entail": 0.1853894293308258,
      "p_contr": 0.009143541567027569,
      "p_neut": 0.8054670095443726,
      "NLIScore": 0.17624588776379824
    },
    {
      "doc_id": "NCT01314963",
      "section": "Intervention",
      "claim_id": "1943100e-196d-4022-a38a-9ae0dd816294",
      "claim_text": "The difference between intervention one and two of the primary trial is that intervention 1 uses higher doses of radioactive Tc99M sulfur colloid than intervention 2.",
      "pred_label": "entailment",
      "gold_label": "contradiction",
      "matched_span": "  radioactive Tc99M: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site. INTERVENTION 2:    Gamma Probes (GP)   Lymphoscintigraphy with standard of care intraoperative gamma probes (GP)   radioactive Tc99M: Lymphoscintigraphy involves injection of 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid around at the tumor site.",
      "span_granularity": "paragraph",
      "p_entail": 0.030714763328433037,
      "p_contr": 0.011363650672137737,
      "p_neut": 0.95792156457901,
      "NLIScore": 0.0193511126562953
    },
    {
      "doc_id": "NCT01451632",
      "section": "Intervention",
      "claim_id": "17660aaf-9218-4119-b00c-f3b863718e97",
      "claim_text": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.0020873332396149635,
      "p_contr": 0.0032542336266487837,
      "p_neut": 0.9946584105491638,
      "NLIScore": -0.0011669003870338202
    },
    {
      "doc_id": "NCT01451632",
      "section": "Intervention",
      "claim_id": "113abff0-a728-40a6-b637-8bd60a53e626",
      "claim_text": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "INTERVENTION 1:    Part 1: Cohort 1   MM-121: 12 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW INTERVENTION 2:    Part 1: Cohort 2a   MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW",
      "span_granularity": "full-document",
      "p_entail": 0.38027989864349365,
      "p_contr": 0.05806215479969978,
      "p_neut": 0.5616579055786133,
      "NLIScore": 0.32221774384379387
    },
    {
      "doc_id": "NCT01451632",
      "section": "Intervention",
      "claim_id": "17660aaf-9218-4119-b00c-f3b863718e97",
      "claim_text": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "INTERVENTION 1: ",
      "span_granularity": "sentence",
      "p_entail": 0.0020873332396149635,
      "p_contr": 0.0032542336266487837,
      "p_neut": 0.9946584105491638,
      "NLIScore": -0.0011669003870338202
    },
    {
      "doc_id": "NCT01451632",
      "section": "Intervention",
      "claim_id": "113abff0-a728-40a6-b637-8bd60a53e626",
      "claim_text": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "INTERVENTION 1:    Part 1: Cohort 1   MM-121: 12 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW INTERVENTION 2:    Part 1: Cohort 2a   MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW",
      "span_granularity": "full-document",
      "p_entail": 0.38027989864349365,
      "p_contr": 0.05806215479969978,
      "p_neut": 0.5616579055786133,
      "NLIScore": 0.32221774384379387
    },
    {
      "doc_id": "NCT00662025",
      "section": "Intervention",
      "claim_id": "58165e03-4aa6-4d0c-8256-dbc92ee900c4",
      "claim_text": "CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle",
      "pred_label": "contradiction",
      "gold_label": "neutral",
      "matched_span": "  SUNITINIB+CAPECITABINE",
      "span_granularity": "sentence",
      "p_entail": 0.0028227197472006083,
      "p_contr": 0.004046016838401556,
      "p_neut": 0.9931313395500183,
      "NLIScore": -0.0012232970912009478
    },
    {
      "doc_id": "NCT00662025",
      "section": "Intervention",
      "claim_id": "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90",
      "claim_text": "Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study.",
      "pred_label": "entailment",
      "gold_label": "neutral",
      "matched_span": "  Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study.",
      "span_granularity": "sentence",
      "p_entail": 0.4221591055393219,
      "p_contr": 0.00990378949791193,
      "p_neut": 0.5679371356964111,
      "NLIScore": 0.41225531604140997
    },
    {
      "doc_id": "NCT00662025",
      "section": "Intervention",
      "claim_id": "58165e03-4aa6-4d0c-8256-dbc92ee900c4",
      "claim_text": "CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle",
      "pred_label": "contradiction",
      "gold_label": "contradiction",
      "matched_span": "  SUNITINIB+CAPECITABINE",
      "span_granularity": "sentence",
      "p_entail": 0.0028227197472006083,
      "p_contr": 0.004046016838401556,
      "p_neut": 0.9931313395500183,
      "NLIScore": -0.0012232970912009478
    },
    {
      "doc_id": "NCT00662025",
      "section": "Intervention",
      "claim_id": "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90",
      "claim_text": "Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study.",
      "pred_label": "entailment",
      "gold_label": "entailment",
      "matched_span": "  Sunitinib was administered orally from Day 1 at the starting dose of 37.5 mg/day on a continuous daily dosing schedule in 21-day cycles. Capecitabine was administered orally from Days 1 to 14 every 21 days at a starting dose of 2,000 mg/m^2/day. Participants were monitored for toxicity, and sunitinib and/or capecitabine dosing could be interrupted or reduced according to individual tolerance. Participants with progressive disease (PD) or intolerable toxicity were considered for discontinuation from the study.",
      "span_granularity": "sentence",
      "p_entail": 0.4221591055393219,
      "p_contr": 0.00990378949791193,
      "p_neut": 0.5679371356964111,
      "NLIScore": 0.41225531604140997
    }
  ],
  "metrics": {
    "accuracy": 0.43333333333333335,
    "macro_precision": 0.2881562881562882,
    "macro_recall": 0.3466666666666667,
    "macro_f1": 0.307518115942029
  }
}